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A highly efficient protocol was developed for the synthesis of 3-(indoline-1-carbonyl)-N-(substituted)benzenesulfonamide compounds with 
excellent yields. The in vitro anticancer activity of the new 3-(indoline-1-carbonyl)-N-(substituted)benzenesulfonamide derivatives against 
A549 (lung cancer cell), HeLa (cervical), MCF-7 (breast cancer cell) and Du-145 (prostate cancer cell) cell lines were studied. Most of the 
tested compounds showed anticancer activity (IC50 values ranged between 1.98 and 9.12 µM against different cell lines).  
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INTRODUCTION 
Antibiotic-resistant bacteria are rapidly emerging 
worldwide.1 The indole derivatives are key structural features 
commonly found in biologically active natural products2,3 as 
tryptophan,4 tryptamine5 and auxin.6 It has been reported that 
sharing of the indole 3-carbon in the formation of 
spiroindoline derivatives profoundly enhances the biological 
activity of the formed compounds.7 Moreover, some of the 
compounds containing benzenesulfonamide moiety also 
show a broad spectrum of important biological properties 
such as elastase inhibition,8 carbonic anhydrase inhibition,9 
Clostridium histolyticum collagenase inhibition10 as well as 
herbicides and plant growth regulator effect.11  
Sulfonamides are common motifs in many drugs and 
medicinal compounds and play an essential role in their 
bioactivity.12 Common drugs such as glibenclamide,13 
sultiame,14 and COX-II inhibitors like Piroxicam,15 
Ampiroxicam,16 and Celecoxib17 containing a sulfonyl 
moiety. The sulfonamides have attracted increasing attention 
for their excellent biological activity18-20 including antitumor, 
antibacterial, thrombin inhibition and antifungal activities.21-
23 
In continuation of our previous work on triazoles, 
pyrimidine, thiazoles and thiazolidinones of pharmaceutical 
interest24,25 we report here the synthesis and anticancer 
activity of several new 3-(indoline-1-carbonyl)-N-
(substituted)benzenesulfonamide derivatives. 
RESULTS AND DISCUSSION 
We have synthesized new indole derivatives containing 
sulfonamide linkage. The synthetic methods for the 
preparation of the N-(substituted phenyl)-3-(indoline-1-
carbonyl)benzenesulfonamide derivatives (5a-g) are 
presented at Scheme 1. We have screened peptide coupling 
conditions in (Table 1) to obtain better yield, excellent purity, 
shorter reaction time, avoiding costly reagents and mainly 
reproducibility of yields 
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Scheme 1 Synthesis of N-(substituted phenyl)-3-(indoline-1-
carbonyl)benzenesulfonamides. 3a-5a: R1=2-methyl; 3b-5b: R1=2-
ethyl; 3c-5c: R1=2-CF3, 3d-5d: 2-t-Bu; 3e-5e: R1=indoline, 3f-5f: 
R1=2-Me, 4-t-Bu; 3g-5g: R1=H.  Reagents and conditions: (a) 
sulfonyl chloride, dichloromethane (DCM) 0 0C-rt; (b) substituted 
amine, pyridine, DCM, 0 0C-rt; (c) lithium hydroxide (LiOH), 
tetrahydrofuran (THF), water (H2O), rt; (d) Indoline, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide  (EDCI), diisopropylethyl-
amine (DIPEA), DCM, rt. 
The synthesis of compound 2 was done by treatment of1  
with sulfonyl chloride at 0 0C in DCM for 60 min and room 
temperature for 1 h. The reaction mixture was evaporated 
under reduced pressure and the obtained gummy material was 
washed with an excess of n-hexane. Recrystallization using 
20 % ethyl acetate: n-hexane mixture gave pure 2 as yellow 
solid  
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Table 1.Optimization of peptide coupling reactions (5a-g)  
PyBOP=benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate;TEA=triethylamine; HATU=1-[bis(dimethylamino)-
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate; EDCI=1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, 
HOBt=hydroxybenzotriazole, T3P=propylphosphonic anhydride; DIPEA=diisopropylethylamine; DMF-dimethyformamid; DCM-
dichloromethane; THF-tetrahydrofuran 
 
Table 2. In vitro anticancer screening of the synthesized compounds 4a-4g and 5a-5g against A549, HeLa, MCF-7 and Du-145 cell lines. 
Data are expressed as IC50 (µM)  ± SD (n = 3) 
Compound  A549  HeLa  MCF-7  Du-145  
4a 1.98±0.12 3.83±0.16 3.52±0.06 3.86±0.16 
4b 2.81±0.13 2.92±0.08 2.32±0.22 3.82±0.12 
4c 4.81±0.12 6.32±0.04 4.32±0.06 3.73±0.12 
4d 2.82±0.11  1.99±0.22 2.36±0.12 3.52±0.11 
4e 3.86±0.08 4.38±0.06 3.63±0.12 6.52±0.22 
4f 2.72±0.11 3.87±0.08 4.12±0.06 3.86±0.22 
4g 3.14±0.14 3.98±0.12 4.86±0.11 4.57±0.11 
5a 8.48±0.14 9.12±0.08 7.82±0.08 9.12±0.06 
5b 3.82±0.08 4.13±0.12 3.13±0.11 3.52±0.08 
5c 4.13±0.12 5.16±0.08 6.12±0.12 4.52±0.11 
5d 2.06±0.12  2.12±0.08 2.52±0.16 5.12±0.08 
5e 2.52±0.11 3.52±0.11 4.48±0.08 4.08±0.11 
5f 4.48±0.08 4.98±0.11 5.17±0.22 5.18±0.18 
5g 2.73±0.08 2.12±0.12 2.12±0.08 2.12±0.04 
5-Fluorouracil  1.61±0.12 1.72±0.18 1.81±0.10 1.89±0.12 
 
The synthesis of compounds 3a-3g was performed with 
sulfonamide coupling using variously substituted amines and 
compound 2 in the presence of pyridine as base and DCM as 
solvent at room temperature for 4 h. The reaction mass was 
treated with cold 2 M aq. HCl and the precipitated solids were 
washed with cold diethyl ether and pentane. The white solids 
(3a-3g) yield was varied between 85 and 95 %. The 
compounds 4a-4g were prepared with hydrolysis of the 
compounds 3a-3g using lithium hydroxide, tetrahydrofuran 
and water at room temperature for 10 h. Washing under basic 
conditions and acidifying led to the desired products as white 
solids with the required purity. The compounds 4a-4g yield 
was varied between 80 and 85 %. 
In order to synthesize compounds 5a-5g, a series of 
coupling reagents and bases, and various solvents and 
reaction times were tested. We have varied the molar ratio of 
reagents and bases used to get better yield and purity in order 
to avoid column purifications (Table 1).  
Using 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazo-
lo[4,5-b]py-ridinium 3-oxid hexafluorophosphate (HATU) as 
coupling reagent and DMF as solvent and triethylamine 
(TEA) and diisopropylethylamine (DIPEA) as bases, after 14 
h, the yield of the product was 57 and 55 %, respectively. 
Using benzotriazol-1-yl-oxytripyrrolidino-phosphonium 
hexafluorophosphate (PyBOP) as coupling reagent and THF 
solvent, and TEA and DIPEA as a base, the obtained yields 
were 45 and 50%, respectively. 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) and 
hydroxybenzotriazole (HOBt) as coupling reagents with 
DMF as a solvent, with 2.5 and 4 equiv. of TEA and DIPEA 
as bases for 14 h, gave 62, 78, and 72 and 67 % yields, 
respectively. Propylphosphonic anhydride (T3P) as coupling 
reagent with TEA and DIPEA as bases in DCM gave 50 and 
60 % yield, respectively. When EDCI (1.5 equiv) was used 
together with DIPEA (2.5 equiv) in DCM, the yields were 
95 %. Working up does not require column chromatography, 
no costly reagents are required.  
Coupling Reagent Base Solvent Time, h Yield, % 
HATU (1.1 equiv) TEA (1.2 equiv) DMF 14 57 
HATU (1.1 equiv) DIPEA (1.2 equiv) DMF 14 55 
PyBOP (1.1 equiv) TEA (1.2 equiv) THF 14 45 
PyBOP (1.1 equiv) DIPEA (1.2 equiv) THF 14 50 
EDCI (1.5 equiv ) TEA (2.5 equiv.) DMF 14 62 
HOBt (1.5 equiv) 
EDCI (1.5 equiv) DIPEA (2.5 equiv) DMF 14 72 
HOBt (1.5 equiv) 
EDCI (1.5 equiv) TEA (4 equiv) DMF 14 78 
HOBt (1.5 equiv) DIPEA (4 equiv) DMF 14 67 
T3P (1.2 equiv) TEA (2.5 equiv) DCM 10 50 
T3P (1.2 equiv) DIPEA (2.5equiv) DCM 10 60 
EDCI (1.5 equiv) DIPEA (2.5 equiv) DCM 10 95 
Acid (1 equiv) and Indoline (1.2 equiv) 
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The IC50 values for 4a-4g and 5a-5g are presented in Table 
2, where all compounds exhibit moderate to a good activity 
toward cancer cell lines compared to 5-fluorouracil as a 
positive control. In the case of the human lung cancer cell line 
(A549) compounds 4a, 4b, 4d, 4f, 5d and 5g were the most 
potent with IC50 values ranging from 1.98-2.82 µM. The 4b, 
4d, 5d and 5g compounds showed activity against HeLa cell 
line (IC50 = 1.99-2.92 µM), while in case of the MCF-7 breast 
cancer cell line, the most potent compounds were 4d, 5d and 
5g withIC50values of 2.12-2.52 µM. Lower activity was 
observed for the synthesized compounds on the Du-145 
prostate cancer cell line, where the most potent candidate was 
the compounds 5g with an IC50 value of 2.12 µM.  
Generally, the lung (A549) and cervical (HeLa) cancer cell 
lines were the most sensitive toward the synthesized 
compounds. Regarding broad-spectrum anticancer activity 
reveals that compounds 4b, 4d and 5g were the most active, 
showing effectivity toward all four cell lines. The structure-
activity relationship (SAR) showed that less hindered 
substitutions like methyl and ethyl groups at ortho and para 
position of aromatic rings increase the anticancer activity at 
all four cell lines, while ortho trifluoromethyl and indole 
groups decrease the anticancer activity. Despite steric 
hindrances, 4b, 4d, 5d and 5g show promising anticancer 
activity due to electron donating substituents, and generally, 
the compounds with electron donating groups on the aromatic 
ring have more considerable anticancer activity than the 
compounds with electron withdrawing groups. 
EXPERIMENTAL PART 
Sulfonyl chloride and various solvents were commercially 
available. The chemicals were purchased from Sigma-
Aldrich and Avra labs. Reaction courses were monitored by 
TLC on silica gel precoated F254 Merck plates. Developed 
plates were examined with UV lamps (254 nm). IR spectra 
were recorded on an FT-IR (Bruker). Melting points were 
recorded on SRS Optimelt, melting point apparatus and are 
uncorrected. The 1H and 13C NMR spectra were recorded on 
a 400 MHz Varian NMR spectrometer with DMSO-d6 
solvent. The chemical shifts are reported as δ ppm units 
(TMS). The following abbreviations are used; singlet (s), 
doublet (d), triplet (t), quartet (q), multiplet (m) and broad (br). 
mass spectra were taken with Micromass-Quattro-II of water 
mass spectrometer.   
General experimental procedure for the synthesis of N-(subs-
tituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamides 
(5a-5g)  
Preparation of ethyl 3-(chlorosulfonyl)benzoate (2)  
To a stirred solution of ethyl benzoate (10 g, 67 mmol) in 
DCM (25 mL) cooled to 0 0C, chlorosulfonic acid (9 g, 73 
mmol) was added dropwise and the mixture was stirred for 
1h at the same temperature followed by stirring at room 
temperature for further 1 h. After completion of reaction, the 
reaction mixture was evaporated under reduced pressure and 
the obtained gummy material was washed with excess of 
hexane and crystallized from 20 % ethyl acetate:hexane 
mixture to obtain ethyl 3-(chlorosulfonyl)benzoate (2) as 
white solid which is used further for sulfonamide coupling 
reaction, Yield 54 g (81 %). 
Preparation of ethyl 3-(N-(o-tolyl)sulfamoyl)benzoate (3a)  
To a stirred solution of ethyl 3-(chlorosulfonyl)benzoate 
(2) (3 g, 10.1 mmol) in DCM (5 ml ), pyridine (5 ml) was 
added and the mixture was stirred at room temperature for 10 
min. The reaction mixture was cooled to 0 ⁰C and 2-
methylaniline (1.6 g, 15.16 mmol ) was added dropwise 
followed by stirring at room temperature for 3 h. The reaction 
was monitored by TLC and LCMS, after completion of the 
reaction the reaction mixture was poured into cold 2 M 
aqueous HCl (10 ml) and stirred the mixture for 30 min. The 
obtained solid was filtered and washed with an excess of 
water, cold diethyl ether (10 ml) and cold pentane (10 ml). 
Ethyl 3-(N-(o-tolyl)sulfamoyl)benzoate (2) was obtained as 
white solid. Yield 2.8 g (90 %). 
Preparation of 3-(N-(o-tolyl)sulfamoyl)benzoic acid (4a) 
To a stirred solution of ethyl 3-(N-(o-
tolyl)sulfamoyl)benzoate (3a) (2 g, 5.40 mmol) in THF (10 
ml), water (2 ml) and lithium hydroxide (0.377 g, 18.2 mmol) 
were added and the reaction mixture was stirred for 4 h. The 
progress of the reaction was monitored by TLC and LC-MS. 
After the completion of the reaction, the reaction mixture was 
evaporated under reduced pressure with obtaining a gummy 
material. After adding 10 ml of water, the mixture was 
extracted with diethyl ether (10 ml). The pH of the collected 
aqueous layer was adjusted to 4 by 6 M aq. HCl. A precipitate 
was formed, and the mixture was stirred for 30 min. The 
obtained solid was filtered off, washed it with an excess of 
water, cold diethyl ether (10 ml) and cold pentane (10 ml) to 
obtain the desired 3-(N-(o-tolyl)sulfamoyl)benzoic acid (4a) 
as white solids. Yield 1.6 g (90 %) 
N-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfon-
amide (5a) 
The compound 3-(N-(o-tolyl)sulfamoyl)benzoic acid (4a) 
(0.2 g, 0.65 mmol) was treated with EDCI (0.188 g, 0.98 
mmol) and DIPEA (0.34 ml, 1.96 mmol) in DCM (10 ml). 
Then 2,4-dimethylaniline (0.238 g, 1.96 mmol) was added 
and the mixture was stirred at room temperature for 4 h. The 
reaction was monitored with TLC. 10 ml of cold water was 
added and the mixture was stirred for 10 min, then extracted 
with 10 ml of DCM. The collected organic layer was washed 
with 1 M aqueous HCl and brine (10 ml). Evaporating the 
organic layer, the compound 5a was obtained with 90 % 
purity. Purification was done by washing with 5:95 % of 
DCM:hexane mixture, when the solid obtained was further 
washed with cold diethyl ether (20 ml) and cold pentane (20 
ml).  
3-(Indoline-1-carbonyl)-N-(o-tolyl)benzenesulfonamide (5a) 
White solid (0.242 g, 92 %). LC-MS m/z (%): 393 (M+H). 
1H NMR (400 MHz, DMSO-d6) δ 9.70 (s, 1H), 8.26  (s, 1H), 
8.22  (d, J=7.6  Hz, 1H), 7.81 (d, J=8 Hz, 1H), 7.7 (d, J=8 Hz, 
1H), 7.18-7.13 (m, 4H), 7.1 (d, J=7.6  Hz,  2H), 6.95-6.92 (m, 
2H), 3.60 (t, 2H), 3.16 (t, 2H),  2.14 (s, 3H). HPLC-98.50 % 
RT-5.68 min. 13C NMR (CDCl3, 100 MHz): 17.65, 27.79, 
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51.54, 126.09, 126.38, 126.40, 126.43, 126.58, 129.23, 
129.42, 130.82, 130.89, 131.38, 133.42, 133.62, 134.27, 
134.65, 135.40, 135.41, 135.45, 141.09, 163.93. 
N-(2-Ethylphenyl)-3-(indoline-1-carbonyl)benzenesulfonamide 
(5b) 
White solid, (0.240 g, 92 %) LC-MS m/z (%): 406 (M+H). 
1H NMR (400 MHz, DMSO-d6) δ 9.70  (s, 1H), 8.27  (s, 1H), 
8.22 (d, J=8  Hz, 1H), 7.84 (d, J=8 Hz, 1H), 7.71 (t, J=7.6 Hz, 
1H), 7.21-7.13 (m, 4H), 7.08-7.01 (m, 4H), 3.63 (t, 2H), 3.08 
(t, 2H), 2.16 (q, 2H), 0.96 (t, 3H). HPLC-99.53% RT-9.21 
min. 13C NMR (CDCl3, 100 MHz): 14.39, 18.80, 27.57, 53.18, 
111.2, 120.3, 122.3, 124.5, 126.15, 126.23, 126.62, 126.63, 
126.66, 129.34, 129.46, 131.36, 133.44, 133.67, 133.88, 
135.46, 140.52, 141.13, 164.0. 
3-(Indoline-1-carbonyl)-N-(2-(trifluoromethyl)phenyl)benzene-
sulfonamide (5c) 
White solid, (0.240 g, 94 %). LC-MS m/z (%): 446 (M+H). 
1H NMR (400 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.34 (s, 1H), 
8.26  (d, J=7.2  Hz, 1H), 7.96 (d, J=7.6 Hz, 1H), 7.79 (d, 2H), 
7.58 (t,  J=8 Hz, 1H), 7.49 (t, J=7.8  Hz, 1H), 7.18 (d, J=8  
Hz, 1H), 7.08-7.01 (m, 4H), 3.63 (t, 2H), 3.08 (t, 2H), HPLC-
96.65%RT-4.89 min. 13C NMR (CDCl3, 100 MHz): 27.74, 
52.51, 111.55, 115.07, 119.55, 125.6, 127.08, 127.09, 127.54, 
128.58, 128.59, 129.23, 129.57, 130.86, 131.51, 133.29, 
133.39, 133.59, 133.88, 135.36, 139.51,164.87. 
N-(2-(tert-butyl)phenyl)-3-(indoline-1-carbonyl)benzenesulfon-
amide (5d) 
White solid (0.240 g, 92 %), LC-MS m/z (%): 434 (M+H). 
1H NMR (400 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.32 (s, 1H), 
8.24  (d, J=7.2  Hz, 1H), 7.94 (d, J=7.6 Hz, 1H), 7.77 (d, 2H), 
7.54 (t,  J=8 Hz, 1H), 7.45 (t, J=7.8  Hz, 1H), 7.16 (d, J=8  
Hz, 1H), 7.06-7.02 (m, 4H), 3.61 (t, 2H), 3.06 (t, 2H), 1.43 (s, 
9H). HPLC-99.33% RT-6.18 min. 13C NMR (CDCl3, 100 
MHz): 27.65, 31.3, 53.79, 51.54, 126.09, 126.38, 126.40, 
126.43, 126.58, 129.23, 129.42, 130.82, 130.89, 131.38, 
133.42, 133.62, 134.27, 134.65, 135.40, 135.41, 135.45, 
141.09, 163.93. 
Indolin-1-yl(3-(indolin-1-ylsulfonyl)phenyl)methanone (5e) 
White solid (0.244 g,  94 %). LC-MS m/z (%): 404 (M+H). 
1H NMR (400 MHz, DMSO-d6) δ 8.26  (s, 1H), 8.22  (d, J=7.6  
Hz, 1H), 7.81 (d, J=8 Hz, 1H), 7.7 (t, J=8 Hz, 1H), 7.20-7.15 
(m, 4H), 7.06-7.02 (m, 4H), 4.11 (t, 2H), 3.65 (t, 2H), 3.11 (t, 
2H), 3.06 (t, 2H). HPLC-97.99 %. RT-8.42 min. 13C NMR 
(CDCl3, 100 MHz): 26.65, 27.79, 42.40, 51.54, 111.23, 
126.09, 126.38, 126.40, 126.43, 126.58, 129.23, 129.42, 
130.82, 130.89, 131.38, 133.42, 134.27, 134.65, 135.40, 
135.41, 135.45, 141.09, 163.93. 
N-(4-(tert-butyl)-2-methylphenyl)-3-(indoline-1-carbonyl)-
benzenesulfonamide (5f) 
White solid (0.238 g, 90 %), LC-MS m/z (%): 448 (M+H). 
1H NMR (400 MHz, DMSO-d6) δ 9.62  (s, 1H), 8.27 (s, 1H), 
8.23  (d, J=7.2  Hz, 1H), 7.87 (d, J=7.6 Hz, 1H), 7.73 (d, J=7,6 
Hz, 1H), 7.29 (d, J=8.4 Hz, 2H), 7.06-7.02 (m, 4H), 6.83 (d, 
J=8.4  Hz, 1H), 3.61 (t, 2H), 3.05 (t, 2H), 2.04 (s, 3H), 1.21  
(s, 9H). HPLC-98.67% RT-7.43 min. 13C NMR (CDCl3, 100 
MHz): 27.65, 31.79, 34.21, 52.33, 111.56, 120.19, 123.17, 
125.17, 126.03, 126.29, 126.32, 126.34, 127.64, 129.3, 
129.49, 131.24, 131.95, 133.85, 135.35, 139.56, 141.42, 
148.88, 151.78, 163.81. 
3-(Indoline-1-carbonyl)-N-phenylbenzenesulfonamide (5g) 
(0.244 g, 94 %) as White solid, LC-MS m/z (%): 378 
(M+H). 1H NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H), 8.28  
(s, 1H), 8.24  (d, J=7.6  Hz, 1H), 7.85 (d, J=8 Hz, 1H), 7.70 
(d, J=8 Hz, 1H), 7.16-7.13 (m, 5H), 7.06-7.02 (m, 4H), 3.61 
(t, 2H), 3.05 (t, 2H). HPLC-93.70% RT-7.58 min.13C NMR 
(CDCl3, 100 MHz): 27.34, 53.63, 119.40, 122.34, 125.63, 
126.03, 126.12, 126.29, 126.71, 126.84, 128.2, 129.01, 
129.37, 129.53, 129.94, 130.31, 133.87, 135.11, 136.24, 
140.41, 165.03. 
Anticancer activity 
The synthesized compounds were evaluated for their in 
vitro anticancer activity against human lung cancer cell line 
(A549), cervical (HeLa) cancer cell line, breast cancer cell 
line (MCF-7) and prostate cell line (DU-145) using 5-
fluorouracil as reference drug.26 The IC50 value which 
corresponds to the concentration required for 50% inhibition 
of cell viability was determined.  
Briefly, cells are grown in 96‐well plates in suspension 
and then were exposed for 48 hours to four serial 
concentrations of 1×10-7, 1×10-6, 1×10-5, 1×10-4 and 1×
10-3 M of each compound. Following this, cells were fixed 
and stained with protein binding SRB stain. Excess stain is 
washed out and the bound stain was solubilized, and the 
absorbance was measured at 492 nm in a plate reader. The 
concentration of the compounds that inhibited 50 % of the net 
cell growth was calculated from the dose-response curve 
obtained for each test compound and cell line. IC50 values 
were presented in micromolar (µM) concentration. 5‐
Fluorouracil (5‐Fu) was used as positive control for the 
comparison of cytotoxicity of synthesized compounds. 
Assays were performed in triplicate on three independent 
experiments and their mean 
CONCLUSION 
An effective method was developed which provides easy 
access to new N-(substituted phenyl)-3-(indoline-1-
carbonyl)benzenesulfonamide (5a-g) analogs. The mild 
reaction conditions, good to excellent yields, easiness of 
workup and the available substrates make the reactions to be 
attractive for the preparation of this compound class. The 
compounds (4b, 4d, 5d and5g) show potent anticancer 
activity in all the four cell lines tested.  
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NEW THIAZOLONE DERIVATIVES: DESIGN, SYNTHESIS, 
ANTICANCER AND ANTIMICROBIAL ACTIVITY 
Dattatraya N. Pansare,*[a] Rohini N. Shelke,[a] Mininath C. Khade,[a]  Vrushali N. 
Jadhav[a], Chandraknat D. Pawar,[b]  Rajiv A. Jadhav,[a]  Saroj R. Bembalkar[a] 
 
Keywords: 2-thioxothiazolidin-4-one, 3-fluorobenzaldehyde, amino acids, anticancer, antimicrobial 
In order to explore the anticancer and antimicrobial activity associated with the thiazolone framework, several new (Z)-2-((5-(3-
fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)amino)carboxylic acid derivatives have been synthesized in water as a solvent. All 
synthesized compounds were evaluated for anticancer and antimicrobial activity in vitro. Amongst these, the 3-methylbutanoic and the 3- or 
4-methylpentanoic acid derivatives, the 3-hydroxy-, the 3-(1H-imidazol-4-yl) and the 3-(4-hydroxyphenyl)propanoic acid derivatives and 
the succinic acid derivative showed high antibacterial and antifungal activity. The unsubstituted propanoic acid derivative exhibited 
significant antibacterial activity against B. subtilis and significant antifungal activity against fungal strains, i.e., A. flavus. The in vitro 
anticancer studies revealed that the 3-(hydroxy)-, the 3-(1H-imidazol-4yl)- and the 3-(4-hydroxyphenyl)propanoic acid, or the succinic acid 
derivatives are the most active compounds against MCF-7 and BT-474 human breast cancer cell lines. 
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INTRODUCTION 
Since the last five decade very rapid progress has been 
made in the area of cancer cell biology, though most cancer 
treatments are still multimodal, involving the 
chemotherapy.1  Cancer is the second leading cause of death 
in the world after cardiovascular diseases and it is projected 
to begin the primary cause of death there within the coming 
year.2,3 The breast cancer may be one of the oldest known 
forms of cancerous tumors in humans. Worldwide, breast 
cancer is the most common cancer in women, after skin 
cancer, representing 16 % of all female cancers.4 
The heterocyclic chemistry has great importance for the 
medicinal chemists due to the high therapeutic activity of 
heterocyclic compounds. The compounds containing the 2-
thioxothiazolidin-4-one (rhodanine) ring scaffold has been 
gaining prominence in recent years, because its derivatives 
are known to possess a broad spectrum of pharmacological 
activities, such as antimicrobial,5-9 antidiabetic,10 
anticancer,11-14 antiviral,15,16 antifungal,17 anticonvulsant,18 
anti-tuberculosis19,20 and anti-HIV.21,22 The identification of 
new structures that can be potentially useful in designing 
new, potent selective and less toxic anticancer agent is still a 
significant challenge to medicinal chemistry researchers.23,24 
The recent reports suggested that a chain containing free 
carboxyl group at the rhodanine nucleus had importance in 
the observed anticancer and antimicrobial activity.25,26 
We initiated a program to synthesize thiazolone 
derivatives having amino acids chain as antimicrobial agents. 
In continuation of our work,27we have developed the new 
protocol for the synthesis of (Z)-5-(3-fluorobenzylidene)-2-
thioxothiazolidin-4-one (3) (Scheme 1) by the condensation 
of 2-thioxothiazolidin-4-one and 3-fluorobenzaldehyde. The 
compound (3) was then subjected to a Knoevenagel 
condensation with the appropriate rhodamines synthesized 
using the reported procedure.28,29 
EXPERIMENTAL SECTION 
The compounds 2-thioxothiazolidin-4-one, 3-
fluorobenzaldehyde, anhydrous sodium acetate, 
triethylamine, amino acids, dichloromethane, iodomethane 
and various solvents were commercially available (Sigma-
Aldrich and Avra labs). Reaction courses were monitored by 
TLC on silica gel precoated F254 Merck plates. Developed 
plates were examined with UV lamps (254 nm). IR spectra 
were recorded on an FT-IR (Bruker). Melting points were 
recorded on SRS Optimelt, melting point apparatus and are 
uncorrected. 1H NMR spectra were recorded on a 400 MHz 
Bruker spectrometer and were recorded in DMSO-d6 solvent 
13C NMR spectra were recorded in DMSO-d6 solvent on a 
100 MHz Bruker spectrometer. Chemical shifts are reported 
as δ ppm units (TMS). The following abbreviations are 
used; singlet (s), doublet (d), triplet (t), quartet (q), multiplet 
(m) and broad (br). Mass spectra were taken with 
Micromass-QUATTRO-II of WATER mass spectrometer. 
The general procedure of (Z)-5-(3-fluorobenzylidene)-2-
thioxothia-zolidin-4-one (3) 
In a 100 ml round bottom flask, the equimolar amount of 
the 2-thioxothiazolidin-4-one (1 mmol) and anhydrous 
sodium acetate (1 mmol) were mixed in glacial acetic acid 
(1 ml) with 3-fluorobenzaldehyde. The reaction mixture was 
stirred under reflux condition for 4 h. The progress of the 
reaction was monitored by TLC (20 % ethyl acetate: n-
 
New thiazolone derivatives: synthesis and biological activity        Section A-Research paper 
Eur. Chem. Bull. 2019, 8(1), 7-14    DOI: 10.17628/ecb.2019.8.7-14 8 
hexane). After completion of the reaction, the reaction 
mixture was poured into the ice-cold water. The precipitate 
was filtered, washed with water (3×10 mL), dried, and 
purified by recrystallization from ethanol as a solvent to 
give a 90 % yield. 
Yellow solid. Yield: 90 %. m.p. 198–200 ºC; ES-MS m/z 
(%): 239.29, IR νmax/cm–1: 3010 (NH), 1702 (C=O), 1594 
(C=C), 1483 (C=N), 1436 (C=S), 1279 (C–N). 1H NMR 
(DMSO-d6): δ = 7.30–7.32 (m, 4H, Ar–CH), 7.60 (s, 1H, 
=CH), 13.90 (s, 1H, NH). 13C NMR (DMSO-d6): δ = 113.5, 
114.5, 116.3, 124.7, 130.9, 136.4, 143.2, 163.5, 168.4, 193.7. 
General procedure of (Z)-5-(3-fluorobenzylidene)-2-(methyl-
thio)thiazol-4(5H)-one (4) 
In a 100 ml round bottom flask, the compound (3) (1 
mmol) and triethylamine (1.5 mmol) were added in 
dichloromethane (10 ml) at room temperature. Iodomethane 
(1.5 mmol) was added to the stirred reaction mixture and the 
mixture was stirred for 2 h at room temperature. The 
progress of the reaction was monitored by TLC (10 % 
chloroform: methanol). After completion of the reaction, the 
reaction mixture was concentrated in-vacuo. The residue 
was washed out with water (3×15 mL) to afford the crude 
product. The crude product was recrystallized using ethanol 
as solvent. 
Yellow solid. Yield: 92 %. m.p. 160–162 ºC; ES-MS m/z 
(%): 253.05, IR νmax/cm–1: 1703 (C=O), 1599 (C=C), 1577 
(C=N), 1287 (C=S), 1086 (C–N). 1H NMR (DMSO-d6): δ = 
2.90 (s, 3H, S-CH3), 7.10–7.21 (m, 4H, Ar–CH), 7.82 (s, 1H, 
=CH), 13C NMR (DMSO-d6): δ = 14.5, 113.9, 114.5, 124.1, 
130.9, 136.4, 143.2, 152.0, 162.8, 163.5, 167.4. 
General procedure of (Z)-2-((5-(3-fluorobenzylidene)-4-oxo-
4,5-dihydrothiazol-2-yl)amino) substituted carboxylic acids 
(6a-l). 
In a 100 ml round bottom flask, the compound (4) (1 
mmol), amino acids (5a-l) (1.5 mmol) and potassium 
carbonate  (1.5 mmol) were mixed in water (1 mL) at room 
temperature and the reaction mixture was stirred for 30-55 
min at room temperature. The progress of reaction was 
monitored by TLC (10 % chloroform: methanol). After 
completion of reaction, the reaction mixture was 
concentrated in-vacuo. The residue was washed with water 
(3×15 mL) to afford the crude product. The compounds (6a-
l) were recrystallized from ethanol and isolated as yellowish 
solids. 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-
yl)amino)propanoic acid (6a) 
Yellow solid. Yield: 92 %, m.p. 189–191 ºC; ES-MS m/z 
(%): 294.28, IR νmax/cm–1: 3744 (COOH), 3397 (OH), 1742 
(HO–C=O), 1642 (C=O), 1564 (C=C), 1549 (C=N), 1206 
(C-S), 1086 (C–N).  1H NMR (DMSO-d6): δ = 1.40–1.42 (d, 
3H, C–CH3), 4.55–4.57 (q, 1H, CH), 7.30–7.32 (m, 4H, Ar–
CH), 7.70 (s, 1H, =CH), 10.20 (s, 1H, NH), 12.65 (s, 1H, 
COOH). 13C NMR (DMSO-d6): δ=16.8, 53.5, 113.9, 114.5, 
124.2, 129.7, 132.7, 136.5, 152.1, 158.3, 162.3, 167.7, 174.2. 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-
yl)amino)-3-methylbutanoic acid (6b) 
Yellow solid. Yield: 94 %, m.p. 204–206 ºC; ES-MS m/z 
(%): 322.35, IR νmax/cm–1: 3414 (OH), 3215 (NH), 3013 
(CH–Ar), 1732 (HO–C=O), 1684 (C=O), 1551 (C=C), 1593 
(C=N), 1012 (C-S), 1091 (C–N). 1H NMR (DMSO-d6): δ = 
0.91–0.93 (d, 6H, CH(CH3)2), 1.50–1.52 (m, 1H, CH), 
4.41–4.43 (d, 1H, CH), 7.25–7.27 (m, 4H, Ar–CH), 7.88 (s, 
1H, =CH), 11.62 (s, 1H, NH), 13.12 (s, 1H, COOH). 13C 
NMR (DMSO-d6): δ = 18.8, 30.5, 61.3, 113.8, 114.4, 124.2, 
130.2, 132.3, 135.9, 152.3, 158.1, 162.7, 167.2, 174.2. 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-
yl)amino)-3-methylpentanoic acid (6c) 
Yellow solid. Yield: 92 %, m.p. 165–167 ºC; ES-MS m/z 
(%): 336.38, IR νmax/cm–1: 3398 (OH), 3212 (NH), 3017 
(CH–Ar), 1735 (HO–C=O), 1692 (C=O), 1557 (C=C), 1583 
(C=N), 1013 (C-S), 1097 (C–N).  1H NMR (DMSO-d6): δ = 
0.91–0.93 (t, 3H, CH2–CH3), 1.15–1.17 (d, 3H, CH3) 1.52–
1.54 (m, 2H, CH2), 1.81–1.83 (m, 1H, CH), 4.43–4.45 (d, 
1H, CH), 7.21–7.23 (m, 4H, Ar–CH), 7.80 (s, 1H, =CH), 
11.64 (s, 1H, NH), 13.29 (s, 1H, COOH). 13C NMR 
(DMSO-d6): δ = 11.2, 15.4, 25.7, 36.4, 58.4, 113.4, 114.5, 
124.9, 130.6, 132.3, 135.9, 152.9, 158.1, 162.4, 167.3, 175.2. 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)-
amino)-3-phenylpropanoic acid (6d) 
Yellow solid. Yield: 90 %, mp 138–140 ºC; ES-MS m/z 
(%): 370.40, IR νmax/cm–1: 3396 (OH), 3211 (NH), 2992 
(CH–Ar), 1737 (HO–C=O), 1692 (C=O), 1551 (C=C), 1581 
(C=N), 1017 (C-S), 1098 (C–N). 1H NMR (DMSO-d6): δ = 
2.51–2.53 (d, 2H, CH2), 4.45–4.47 (q, 1H, CH), 7.25–7.27 
(m, 9H, Ar–CH), 7.89 (s, 1H, =CH), 11.75 (s, 1H, NH), 
13.31 (s, 1H, COOH). 13C NMR (DMSO-d6): δ = 36.4, 58.4, 
113.5, 114.6, 124.9, 125.9, 125.7, 128.6, 128.9, 130.7, 132.3, 
135.3, 136.9, 152.2, 158.5, 167.1, 175.2. 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)-
amino)-4-(methylthio)butanoic acid (6e) 
Yellow solid. Yield: 92 %, mp 142–144 ºC; ES-MS m/z 
(%): 354.42, IR νmax/cm–1: 3396 (OH), 3210 (NH), 2980 
(CH–Ar), 1732 (HO–C=O), 1698 (C=O), 1541 (C=C), 1586 
(C=N), 1014 (C-S), 1091 (C–N). 1H NMR (DMSO-d6): δ = 
2.01–2.03 (q, 2H, CH2), 2.20 (s, 3H, CH3), 2.61–2.63 (t, 2H, 
CH2), 4.43–4.45 (q, 1H, CH), 7.30–7.32 (m, 4H, Ar–CH),  
7.78 (s, 1H, =CH), 11.61 (s, 1H, NH), 13.15 (s, 1H, COOH). 
13C NMR (DMSO-d6): δ = 15.3, 29.8, 30.5, 56.8, 113.5, 
114.6, 124.9, 127.7, 128.6, 136.9, 152.2, 158.5, 162.4, 167.3, 
174.7. 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)-
amino)-4-methylpentanoic acid (6f) 
Yellow solid. Yield: 94 %, mp 187–189 ºC; ES-MS m/z 
(%): 336.38, IR νmax/cm–1: 3397 (OH), 3217 (NH), 3011 
(CH–Ar), 1736 (HO–C=O), 1695 (C=O), 1555 (C=C), 1583 
(C=N), 1013 (C-S), 1091 (C–N). 1H NMR (DMSO-d6): δ = 
0.92–0.94 (d, 6H, CH–(CH3)2), 1.41–1.43 (m, 1H, CH), 
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1.71–1.73 (t, 2H, CH2), 4.44–4.46 (q, 1H, CH), 7.29–7.31 
(m, 4H, Ar–CH), 7.76 (s, 1H, =CH), 11.72 (s, 1H, NH), 
13.35 (s, 1H, COOH). 13C NMR (DMSO-d6): δ = 22.7, 24.4, 
40.3, 55.4, 113.4, 114.4, 124.9, 129.2, 132.1, 135.4, 152.2, 
159.1, 162.3, 167.1, 174.2. 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)-
amino)-3-hydroxypropanoic acid (6g) 
Yellow solid. Yield: 96 %, m.p. 185–187 ºC; ES-MS m/z 
(%): 310.30, IR νmax/cm–1: 3450 (OH), 3211 (NH), 3008 
(CH–Ar), 1738 (HO–C=O), 1688 (C=O), 1551 (C=C), 1511 
(C=N), 1019 (C-S), 1097 (C–N). 1H NMR (DMSO-d6): δ = 
3.62 (s, 1H, CH), 4.02–4.04 (t, 1H, CH), 4.23–4.25 (d, 2H, 
CH2), 7.31–7.33 (m, 4H, Ar–CH), 7.93 (s, 1H, =CH), 11.60 
(s, 1H, NH), 13.13 (s, 1H, COOH). 13C NMR (DMSO-d6): δ 
= 59.2, 62.2, 113.4, 114.4, 124.9, 129.2, 130.3, 132.1, 136.4, 
151.9, 158.1, 167.9, 172.2. 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)-
amino)-3-mercaptopropanoic acid (6h) 
Yellow solid. Yield: 94 %, mp 179–181 ºC; ES-MS m/z 
(%): 326.70, IR νmax/cm–1: 3455 (OH), 3201 (NH), 3017 
(CH–Ar), 2500 (SH), 1738 (HO–C=O), 1695 (C=O), 1559 
(C=C), 1503 (C=N), 1014 (C-S), 1095 (C–N). 1H NMR 
(DMSO-d6): δ = 1.50 (s, 1H, SH), 3.11–3.13 (d, 2H, CH2), 
4.13–4.15 (t, 1H, CH), 7.22–7.24 (m, 4H, Ar–CH), 7.68 (s, 
1H, =CH), 11.61 (s, 1H, NH), 13.11 (s, 1H, COOH). 13C 
NMR (DMSO-d6): δ = 26.3, 60.4, 113.4, 114.4, 124.9, 127.5, 
132.5, 135.6, 152.9, 158.3, 162.3, 167.2, 178.2. 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)-
amino)succinic acid (6i) 
Yellow  solid. Yield: 92 %, mp 214–216 ºC; ES-MS m/z 
(%): 338.40, IR νmax/cm–1: 3464 (OH), 3213 (NH), 3020 
(CH–Ar), 1732 (HO–C=O), 1689 (C=O), 1549 (C=C), 1503 
(C=N), 1030 (C-S), 1089 (C–N).  1H NMR (DMSO-d6): δ = 
2.60–2.62 (d, 2H, CH2), 3.71–3.73 (t, 1H, CH), 7.35–7.37 
(m, 4H, Ar–CH), 7.88 (s, 1H, =CH), 11.70 (s, 1H, NH), 
13.12 (s, 2H, COOH). 13C NMR (DMSO-d6): δ = 35.9, 53.3, 
113.4, 114.4, 124.9, 130.1, 132.5, 135.6, 136.4, 152.9, 158.3, 
162.3, 167.2, 178.2. 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)-
amino)-3-(1H-imidazol-4-yl)propanoic acid (6j) 
Yellow solid. Yield: 94 %, m.p. 152–154 ºC; ES-MS m/z 
(%): 360.38, IR νmax/cm–1: 3435 (OH), 3215 (NH), 3011 
(CH–Ar), 1739 (HO–C=O), 1681 (C=O), 1552 (C=C), 1508 
(C=N), 1033 (C-S), 1092 (C–N). 1H NMR (DMSO-d6): δ = 
2.92–3.94 (d, 2H, CH2), 3.73–3.86 (t, 1H, CH), 7.31–7.33 
(m, 4H, Ar–CH), 7.77 (s, 1H, =CH), 7.86 (s, 1H, =CH), 8.98 
(s, 1H, =CH), 11.62 (s, 1H, NH), 13.12 (s, 1H, NH), 13.34 
(s, 1H, COOH).  13C NMR (DMSO-d6): δ = 28.9, 58.3, 
113.4, 114.4, 117.9, 124.9, 124.7, 124.7, 127.9, 128.6, 132.1, 
136.2, 152.3, 158.2, 167.5, 176.2. 
 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-
yl)amino)-3-(4-hydroxyphenyl)propanoic acid (6k) 
Yellow solid. Yield: 92 %, m.p. 212–214 ºC; ES-MS m/z 
(%): 386.44, IR νmax/cm–1: 3462 (O=C-OH), 3392 (OH), 
3211 (NH), 2992 (CH–Ar), 1732 (HO–C=O), 1697 (C=O), 
1553 (C=C), 1591 (C=N), 1011 (C-S), 1089 (C–N). 1H 
NMR (DMSO-d6): δ = 2.80–2.98 (d, 2H, CH2), 4.43–4.45 (t, 
1H, CH), 5.30 (s, 1H, OH), 7.30–7.32 (m, 8H, Ar–CH),  
7.87 (s, 1H, =CH), 11.72 (s, 1H, NH), 13.32 (s, 1H, COOH). 
13C NMR (DMSO-d6): δ = 36.3, 58.6, 113.9, 114.7, 115.8, 
127.7, 128.9, 129.2, 130.2, 135.3, 136.9, 152.2, 155.7, 158.5, 
162.7, 167.8, 174.3. 
(Z)-2-((5-(3-Fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-
yl)amino)-3-hydroxybutanoic acid (6l) 
Yellow solid. Yield: 90 %, m.p. 173–175 ºC; ES-MS m/z 
(%): 324.56, IR νmax/cm–1: 3462 (OH), 3201 (NH), 3010 
(CH–Ar), 1733 (HO–C=O), 1682 (C=O), 1534 (C=C), 1516 
(C=N), 1042 (C-S), 1115 (C–N).  1H NMR (DMSO-d6): δ = 
1.10–1.12 (d, 3H, CH3), 3.51–3.55 (d, 1H, CH), 3.63 (s, 1H, 
OH), 3.93–3.95 (m, 1H, CH), 7.25–7.27 (m, 4H, Ar–CH), 
7.75 (s, 1H, =CH), 11.60 (s, 1H, NH), 13.10 (s, 1H, COOH). 
13C NMR (DMSO-d6): δ = 19.6, 64.3, 66.5, 113.9, 114.7, 
124.8, 130.3, 132.4, 136.1, 152.2, 158.3, 162.4, 167.8, 174.2. 
Antimicrobial tests 
The antimicrobial activity of compounds were tested 
against six bacteria; Bacillus subtilis (NCIM-2063), 
Staphylococcus aureus (NCIM-2901), Escherichia coli 
(NCIM-2256), Enterococcus faecalis (NCIM-5443), 
Pseudomonas aeruginosa (NCIM-2037), Salmonella 
typhimurium (NCIM-2501) and six fungal strains; 
Aspergillus  oryzae (NCIM-570), Penicillium  chrysogenum 
(NCIM-707), Fusarium oxysporum (NCIM-1282), Candida 
albicans (NCIM-3471),  Aspergillus flavus (NCIM-539) and 
Aspergillus niger (NCIM-1196). The antibacterial activity of 
compounds was monitored by observing their Minimum 
inhibitory concentration (MIC, μg mL-1) as previously 
mentioned30 by broth dilution methods with Ciprofloxacin 
and Ampicillin as control drugs.  
The antifungal study was carried by the standard agar 
dilution method and Fluconazole and Miconazole were used 
as control drugs. Ethanol was used as solvent control for 
both antibacterial and antifungal testing. 
All the synthesized compounds were also tested for their 
general cytotoxicity on MCF-7 and BT-474 human breast 
cancer cell line. This test is performed as previously 
mentioned MTT colorimetric assay.31  Cytotoxicity of the 
compounds was determined by calculating their IC50 values 
(μM mL-1), the concentration of compound required to 
inhibit 50 % of cell growth compared to untreated control 
cells. The results are given as percentage cytotoxicity after 
24 h. Adriamycin was used as positive control for the 
comparison of cytotoxicity of synthesized compounds. 
Assays were performed in triplicate on three independent 
experiments. 
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RESULT AND DISCUSSION  
Several new (Z)-2-((5-(3-fluorobenzylidene)-4-oxo-4,5-
dihydrothiazol-2-yl)amino) substituted organic acid 
derivatives (6a-l) were synthesized and characterized by 1H 
and 13C NMR, IR spectroscopy.  
A new protocol for the synthesis of (Z)-5-(3-
fluorobenzylidene)-2-thioxothiazolidin-4-one (3) by the 
condensation of 2-thioxothiazolidin-4-one and 3-
fluorobenzaldehyde as the initial step of the reaction route 
has been developed.  
Table 1. Physical data of the synthesized compounds 3, 4 
and 6a-la 
aReaction condition (6a-l): Compound (4) (1 mmol), amino acids 
(5a-l) (1.5 mmol), K2CO3 (1.5 mmol), 1 ml water at room 
temperature.bIsolated yields 
The compound (3) was then subjected to a Knoevenagel 
condensation with the appropriate 2-thioxothiazolidin-4-one, 
to synthesize a new series of target compounds (6a-l). 
 
 
Scheme 1 Synthesis of (Z)-2-((5-(3-fluorobenzylidene)-4-oxo-4,5-
dihydrothiazol-2-yl)amino) substituted acid (6a-l). 
The structures of the desired compounds were confirmed 
by IR, 1H NMR and 13C NMR. The compound 3 was 
prepared in prominent good yields via a Knoevenagel 
condensation between the corresponding heterocyclic cores 
of Rhodanine and 3-fluorobenzaldehyde (Scheme 1). 
The 2-thioxothiazolidin-4-one based compounds were 
synthesized by conventional heating with sodium acetate, 
which acts as a base and glacial acetic acid as catalysts. In 
theory, of E and Z geometrical isomers may exist according 
to the configuration around the exocyclic double bond 
(CH=C) for (Z)-5-(3-fluorobenzylidene)-2-thioxothia-
zolidin-4-one (3). 
The 1H NMR spectrum of the compound 3 shows only 
one signal for the methine proton in the range δ 7.66, which 
show the presence of one isomer only, and at lower field 
values than those expected for the E-isomers, which was 
strongly indicated that the compounds have the Z-
configuration. The IR spectrum of compound 3, showed a 
strong absorption band at 1702 cm-1 that is due to a carbonyl 
group. The mass spectrum revealed a molecular ion peak at 
m/z=239.29 corresponding to a molecular formula 
C10H6FNOS2. The latter has been reported as 
thermodynamically more stable than the E-
configuration.32,33 
Compound 4 was synthesized from compound 3 and 
the structures of the desired product were confirmed by IR, 
1H NMR, 13C NMR and mass spectral analysis. The IR 
spectrum of (Z)-5-(3-fluorobenzylidene)-2-(methylthio)-
thiazol-4(5H)-one (4), showed a strong absorption band at 
1704 cm-1 belongs to a carbonyl group. The mass spectrum 
revealed a molecular ion peak at m/z = 253.05 
corresponding to a molecular formula C11H8FNOS2. The 1H 
NMR spectra of the compound 4 show only one signal for 
the methine proton in the range δ 7.82, sulfur attached 
methyl group proton shows a singlet at δ 2.85.  
We synthesized a series of new (Z)-2-((5-(3-
fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)amino) 
substituted carboxylic acids (6a-l) from the compound 4 and 
different types of amino acids (5a-l), (Scheme 1, Table 1). 
The displacement of a methylthio group by various amino 
acids from the C2 position of the thiazolone ring and the 
structures of the desired compounds (6a-l) were confirmed 
by IR, 1H NMR, 13C NMR analysis.  
The IR spectrum of (Z)-2-((5-(3-fluorobenzylidene)-4-
oxo-4,5-dihydrothiazol-2-yl)-amino)propanoic acid (6a), 
showed a strong absorption band at 1742 cm-1 belongs to the 
carbonyl of a carboxylic group and 3397 cm-1 due to the 
presence hydroxyl group. The mass spectrum revealed a 
molecular ion peak at m/z=294.28 corresponding to a 
molecular formula C13H11FN2O3S. The 1H NMR spectrum 
revealed that the signals of 6a (as a representative example), 
show the methyl group protons doublet in the range of δ 
1.40–1.50, the methine proton (adjacent to carboxylic acid 
group) shows a quartet in the range of δ 4.50–4.70, phenyl 
ring protons show a multiplet in the range of δ 7.40–7.70, 
one signal appears for the alkene proton in the range δ 7.72, 
amine group proton shows singlet at δ 10.10, and the 
carboxylic acid proton shows singlet at δ 12.65. 
Comp
. 
Substituent (R) Time, 
min 
Yield,
%b 
M.P., ºC 
3 - 240 90 198-200 
4 - 120 92 160-162 
6a -CH3 35 92 189-191 
6b -CH(CH3)2 30 94 204-206 
6c -CH(CH3)CH2CH3 35 92 165-167 
6d -CH2C6H5 35 90 138-140 
6e -CH2CH2SCH3 40 92 142-144 
6f -CH2CH(CH3)2 55 94 187-189 
6g -CH2OH 50 96 185-187 
6h -CH2SH 40 94 179-181 
6i -CH2COOH 50 92 214-216 
6j 3-(1H-imidazol-4yl) 35 94 152-154 
6k -CH2C6H4OH 45 92 212-214 
6l -CHOHCH3 35 90 173-175 
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Table 2. Antibacterial activity of synthesized compounds 3, 4 and 6a-6l 
Compound  B.s. S.a. E.c. E.f. P.a. S.t. 
3 MIC 35.70 35.57 10.37 34.70 30.90 30.95 
 MBC 55.13 56.15 36.40 46.14 33.76 34.75 
4 MIC 31.70 31.50 31.39 35.13 35.30 33.90 
 MBC 45.13 45.17 45.40 45.12 55.73 31.75 
6a MIC 36.14 36.12 33.17 34.16 28.35 28.35 
 MBC 44.55 44.56 44.53 47.54 37.16 32.18 
6b MIC 7.10 13.10 48.40 48.10 52.13 52.15 
 MBC 18.20 23.30 69..40 63.10 52.20 51.90 
6c MIC 55.70 56.57 56.37 33.70 33.90 6.85 
 MBC 58.14 58.16 48.40 58.10 38.76 19.85 
6d MIC 33.70 33.50 32.39 35.10 25.30 37.90 
 MBC 48.15 47.10 47.40 47.10 58.60 32.70 
6e MIC 9.50 8.75 30.10 34.10 28.50 27.30 
 MBC 32.10 32.10 48.50 48.50 32.70 33.10 
6f MIC 7.45 8.78 48.40 48.10 52.13 52.15 
 MBC 16.20 20.30 59..40 60.10 55.20 56.90 
6g MIC 38.70 38.57 19.37 38.70 32.90 6.95 
 MBC 54.13 55.15 35.40 58.10 37.76 18.75 
6h MIC 33.70 33.50 33.39 35.10 26.30 36.90 
 MBC 47.10 47.15 47.47 48.10 58.60 32.70 
6i MIC 9.50 8.10 30.10 34.10 28.50 27.30 
 MBC 34.10 34.10 48.50 45.50 35.70 33.10 
6j MIC 7.10 8.50 38.40 38.10 42.13 51.15 
 MBC 16.20 20.30 59..40 60.10 55.20 56.90 
6k MIC 38.70 38.57 18.37 39.70 33.90 8.95 
 MBC 59.13 54.15 36.40 36.10 36.76 16.75 
6l MIC 37.10 38.10 39.40 36.10 32.13 32.15 
 MBC 44.20 42.30 58..40 63.10 55.20 56.90 
Ciprofloxacin  MIC 14.70 13.69 12.69 15.69 11.69 15.69 
 MBC 33.19 33.10 22.10 32.10 14.10 34.10 
Ampicillin MIC 3.71 3.20 3.20 3.20 3.86 3.46 
 MBC 5.29 5.43 1.43 1.43 2.71 1.86 
aValues are the average of three readings. MIC= minimal inhibitory concentration, in mg L-1, MBC = 1.43-5.43 in mg L-1. B.s.- Bacillus 
subtilis (NCIM-2063), S.a.-Staphylococcus aureus (NCIM-2901), E.c.- Escherichia coli (NCIM-2256), E.f. - Enterococcus faecalis 
(NCIM-5443), P.a.- Pseudomonas aeruginosa (NCIM-2037), S.t.-  Salmonella typhimurium (NCIM-2501) 
 
The antimicrobial activities of the synthesized compounds 
against selected Gram-positive and Gram-negative bacteria 
and multidrug-resistant bacteria are illustrated in Table 2 
and Table 3. The majority of the synthesized compounds 
show a variety of antibacterial, antifungal and cytotoxic 
activity. The compounds 3 was found to be the most active 
against E. coli and the compounds 6c, 6g and 6k were found 
to be active against S. typhimurium. 
Some of the studied compounds are more potent against 
selected microorganisms than a standard antibacterial drug 
Ciprofloxacin. For example, against E. Coli the compound 3 
while against B. subtilis the compounds 6b, 6e, 6f, and 6j 
have better MIC values than the values found for 
Ciprofloxacin. Against S. aureus, the compounds 6b, 6e, 
6f,6i and 6j proved to be more active than Ciprofloxacin.  
The compounds 6g and 6k showed antifungal activity 
against four fungus strains, namely A. oryzae, P. 
chrysogenum, C. albicans and A. flavus. The compound 6a 
showed activity against A. flavus, the compound 6c against 
P. Chrysogenum and F. oxysporum while the compound 6e 
was found to be active against P. chrysogenum. Remaining 
compounds of the series (3, 4, 6d, 6f, 6h, 6i, 6j and 6l were 
found to be inactive against fungi.  
All the synthesized compounds were tested for their 
cytotoxic activity against MCF-7 and BT-474 cell lines 
(Table 4). (Table 4). Three compounds, 6g, 6i and 6l 
showed good activity against the studied cancer cell lines, 
the IC50 values against MFC-7 and BT-474 cell lines were 
found to be 1.4 and 1.3, 1.5 and 0.6, or 1.1 and 1.4 µM mL-1, 
respectively. The IC50 values for reference drug Adriamycin 
against MFC-7 and BT-474 cells were found to be 0.9 and 
0.5 µM mL-1, respectively. The cytotoxicity of the newly 
synthesized thiazolones depends on the type of substituents 
on thiazolone moiety. The compounds containing hydroxyl 
groups attached to the amino acid parts linked to the 
thiazolone ring have the highest cytotoxic activity. The 
presence of electron releasing alkyl chain, methyl-1H-
imidazole ring or thiol group on the amino acid attached to 
the thiazolone rings resulted in the loss of activity.  
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Table 3. Antifungal activity of synthesizing compounds 3, 4 and 6a-l 
aValues are the average of three readings. A.o.- Aspergillus oryzae (NCIM-570), P.c.- Penicillium chrysogenum (NCIM-707), F.o.- 
Fusarium oxysporum (NCIM-1282), C.a.- Candida albicans (NCIM-3471),  A.f.- Aspergillus flavus (NCIM-539) and A.n.- Aspergillus 
Niger (NCIM-1196). 
 
Structure-activity relationship (SAR) 
The results of the antimicrobial screening demonstrated 
some facts about the structural-activity relationship (SAR) 
of the synthesized thiazolone derivatives. The notable 
highlights of structure-activity relationship are the 
followings: 
The biological activity profile of molecules is strongly 
affected by the branching pattern and chain length of alkyl 
moieties. Attachment of a methyl group at C2 position on 
the thiazolone moiety (6a) makes molecule active against 
bacterial and fungal strains, probably due to its small size 
and electron donating effects. When this methyl group is 
replaced by isopropyl (6b) and 2-methylbutyl (6c) groups, 
the molecules become active on a broader spectrum (against 
the majority of the studied strains). This shows that the 
presence of branching at the carbon located on the C2 
position of the thiazolone ring has a positive effect on 
appearing or strengthening of antimicrobial activity. 
Attachment of 2-methylpropyl group (6f) at the same 
position makes the molecule to be specific towards the B. 
subtilis and S. aureus. Substitution of the alkane chain with 
a carboxylic group (6i), also resulted in specificity towards 
B. subtilis and S. aureus. 
Table 4. In vitro cytotoxicity of compounds towards the MCF-7 
and BT-474 cells, after 24 h. 
aGI50(Growth inhibition of 50 %): Concentration of drug that 
decreases the growth of the cells by 50 % compared to a non-
treated control cell. bValues are the average of three readings; 
cMCF-7: Human Breast cancer cell line, dBT-474: Human Breast 
cancer cell line; e-Adriamycin: positive control compound 
Compound  A.o. P.c. F.o. C.a. A.f. A.n. 
3 MIC 32.50 52.39 34.50 34.50 18.30 18.30 
 MFC 53.10 53.10 74.12 54.10 35.20 75.33 
4 MIC 37.00 37.20 33.20 33.20 33.20 30.00 
 MFC 36.20 46.60 81.10 42.30 34.88 35.00 
6a MIC 31.50 31.39 31.50 34.50 12.30 19.30 
 MFC 46.10 46.10 62.12 32.10 33.20 41.33 
6b MIC 33.00 31.20 31.20 32.20 32.20 34.00 
 MFC 43.20 44.50 45.10 66.30 33.88 48.00 
6c MIC 35.50 17.39 17.50 57.50 36.30 39.30 
 MFC 49.40 34.40 34.32 36.30 34.30 35.33 
6d MIC 32.30 35.40 32.30 57.50 67.50 34.50 
 MFC 42.30 52.20 84.10 52.00 72.30 51.50 
6e MIC 36.30 13.80 51.20 31.25 44.25 30.55 
 MFC 36.80 34.70 65.18 60.18 30.64 45.69 
6f MIC 34.00 34.20 34.20 55.20 34.70 31.00 
 MFC 43.20 44.60 49.10 65.35 35.88 48.00 
6g MIC 5.55 16.36 39.50 18.50 16.30 36.30 
 MFC 10.10 44.10 32.11 35.10 32.22 32.23 
6h MIC 32.00 32.50 34.40 68.40 58.10 34.40 
 MFC 51.34 52.25 84.15 72.05 33.30 54.50 
6i MIC 42.35 55.80 41.26 31.26 74.26 35.58 
 MFC 55.80 35.78 62.38 62.38 32.84 43.29 
6j MIC 43.40 34.24 54.26 34.66 34.26 33.07 
 MFC 53.25 42.65 43.15 64.48 33.89 58.08 
6k MIC 34.55 17.30 16.50 16.50 16.30 33.30 
 MFC 45.10 33.75 53.52 32.10 34.20 35.33 
6l MIC 42.00 32.60 62.50 59.50 58.70 34.00 
 MFC 58.30 55.20 64.10 62.50 62.30 51.50 
Fluconazole MIC 5.60 1.68 28.65 5.70 9.42 2.28 
 MFC 9.35 5.75 46.00 9.62 17.80 5.75 
Miconazole MIC 40.25 5.30 7.18 1.34 43.20 156.30 
 MFC 85.18 151.28 20.20 6.18 142.20 140.12 
  
Sr. No. Compounds IC50,
a  µMb 
MCF-7c BT-474d 
1 3 38.6 53.4 
2 4 54.8 25.0 
3 6a 44.9 43.4 
4 6b 46.2 62.2 
5 6c 56.3 56.6 
6 6d 82.4 48.6 
7 6e 76.5 48.6 
8 6f 82.4 56.8 
9 6g 1.4 0.6 
10 6h 72.2 77.1 
11 6i 1.3 1.1 
12 6j 78.7 74.5 
13 6k 10.1 10.0 
14 6l 1.5 1.4 
 Adriamycin 0.9 0.5 
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Substitution by phenylmethyl group (6d) at the C2 
position of the thiazolone moiety gave completely inactive 
molecule towards all tested strains, while the 4-
hydroxyphenyl (6k) substitution made the molecule to be 
active towards S. typhimurium, and P. chrysogenum,  F. 
oxysporum, C. Albicans and A. flavus. The compound (6j) 
containing methyl-imidazole ring at the C2 position of the 
thiazolone moiety resulted in appearing of specific activity 
towards the Gram-positive bacteria B. subtilis and S. aureus. 
The compound (6e) with the terminal methylthio group is 
active toward.B. subtilis, S. aureus and P. chrysogenum, 
while compound (6h) with terminal mercapto group was 
proved to be inactive towards these bacterial and fungal 
strains.  
CONCLUSION 
The objective of our present study is to synthesize and 
investigation of the potent anticancer and antimicrobial 
activities of some new (Z)-2-((5-(3-fluorobenzylidene)-4-
oxo-4,5-dihydrothiazol-2-yl)amino) substituted organic 
acids. 
This is the first reported synthesis of the (Z)-2-((5-(3-
fluorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)amino) 
substituted organic acids in water as solvent with excellent 
yields in shorter reaction time making the process 
economically lucrative for industrial application. Some 
derivatives were found to be more active against several 
bacteria and fungi strains than the common antimicrobial 
agents.  
In vitro anticancer studies revealed that the compounds 6g, 
6i, 6k and 6l are most active against MCF-7 and BT-474 
human breast cancer cell lines.  
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HYPOGLYCAEMIC ACTIVITY OF VERNONIA AMYGDALINA 
(DEL.) EXTRACTS IN NORMAL AND ALLOXAN-INDUCED 
RATS  
Junias  B. Vopnu,[a] Edoho J. Edoho[a]and Olawale  H. Oladimeji[a] 
Keywords: Normo-glycaemic; alloxan; extracts; diabetes mellitus; hypoglycaemic. 
Vernonia amygdalina (Del.) is widely cultivated in tropical Africa and known for its bitter principles. The extracts of this plant are used in 
folklore medicine to treat fevers, measles, tuberculosis, toothaches, parasitic infections, asthma, diarrhoea and in managing diabetes mellitus. 
The growing concerns arising from the treatment and management of the diabetes prompted this study. Hence, the hypoglycaemic potentials 
of leaf, stem and root (squeezed and methanolic) extracts of the plant were investigated in normo-glycaemic and alloxan-induced rats. The 
blood glucose levels in normal and diabetic rats were determined after the administration of 300mg/kg of extract and 150mg/kg of alloxan 
monohydrate at time (t) = 0, 1, 2 and 4 h. The hypoglycaemic activities of the squeezed extracts of leaves, stem and roots were not significant 
in both normal and diabetic rats. However, the methanolic extracts of the leaves and roots demonstrated significantly remarkable 
hypoglycaemic activities compared with the activity given by the stem extract. The methanolic extracts of leaves and root have shown to be 
effective in lowering blood glucose level (80% reduction after 4h) while the stem afforded a poorly 20% reduction after 4 h. The results from 
this study have lent scientific credence to the ethnobotanical use of the plant in the treatment and management of diabetes mellitus. However, 
the claims that the stem is as effective in the herbal therapy of this metabolic disease can not be supported by the results obtained from this 
study.  
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INTRODUCTION 
Medicinal plants are undoubtedly relevant in both 
developing and developed nations of the world as sources of 
herbal drugs for treating and managing various ailments and 
disease conditions. Herbal medicines are finished, labelled 
medicinal products which contain plant parts whether in the 
crude state or slightly processed state.1 Hence, some plants 
are used for treating such high priority diseases such as 
cardiovascular conditions, sickle cell anaemia, HIV/AIDS, 
renal ailments, tumours and most especially diabetes 
mellitus.2 Many patients who suffer from diabetes mellitus 
are experiencing difficulties in managing the disease 
condition due to several factors including increasing cost and 
uncomfortable side effects of orthodox therapy. In addition, 
the increasing prevalence of this condition in the third world 
means there are more diabetics per orthodox health personnel 
and also increase in visits to diabetic clinics.3-6 
In the light of these realities, there is an urgent need for a 
search for herbal recipes that could be used in the treatment 
and management of this metabolic disorder of the body. 
Vernonia amygdalina (Del.) which is widely grown in 
tropical Africa and known for its ‘bitter principles’7 is used in 
traditional medicine to treat  fevers, measles, tuberculosis, 
toothaches, parasitic infections, asthma, diarrhoea and in 
managing diabetes mellitus.7-10 Also, the extracts of the plant 
have been evaluated for laxative, arbortificient, anti-
helmintic, antithrombotic and anticoagulant properties.7-14   
The plant possesses nutritional values especially in the 
South-Eastern parts of Nigeria where its consumption is 
widespread.8,10-11 Consequently, the present study was 
undertaken to investigate into the hypoglycaemic potentials 
of the leaf, stem and root extracts of V. amygdalina in rats. 
MATERIALS AND METHODS 
Plant Collection and Identification:  
Fresh leaves, stem and roots of V. amygdalina were 
collected within the precinct of the botanical gardens of the 
Faculty of Pharmacy, University of Uyo, Nigeria around July, 
2010. Voucher specimens of the plant (Nos H75-H77) were 
deposited in the herbarium of the Faculty of Pharmacy, 
University of Uyo, Nigeria.   
Extraction  
The fresh leaves of V. amygdalina were macerated with a 
wooden mortal and pestle after washing with water. 200g of 
the macerated leaves was squeezed and the resultant mixture 
filtered with a filter paper (Whatman International, England). 
The filtrate obtained was subsequently concentrated in vacuo 
on a rotary evaporator (Buchi CH-920,  Laboratorium 
Technic, Flawk/SG, Switzerland) and the obtained dried 
powder stored in a silica-gel desiccator prior to further tests. 
Another 200g of the leaf extract was extracted with cold 96 
% aqueous methanol at room temperature (27± 2 0C) for 72h, 
likewise concentrated and stored. The same procedures were 
repeated for the stem and roots.  
Preparation of rats 
Permission was sought from the College of Health 
Sciences’ Animals Ethics Committee, University of Uyo, 
Uyo, Nigeria and approval was granted on the 24th, July, 2010 
as contained in the reference document (UU/CHS/DP/12). 
The animals were then subsequently used in the 
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hypoglycaemic studies. Albino rats of both sexes obtained 
from the University of Uyo, Animal House weighing on the 
average 110.12 ± 10.67g were made diabetic by 
intraperitoneal injection of alloxan monohydrate (150mg/kg). 
The animals were quarantined for 7days to stabilize the blood 
glucose level. The rats were maintained under standard 
laboratory conditions and had free access to feed (Pfizer 
Feeds, Nigeria) and water ad libtum. 
Administration of extracts 
Normoglycaemic rats 
The animals were arranged into seven groups of five rats 
each. The rats were put through a 12 h overnight fast and the 
groups were subsequently treated as follows:     
Group I (control) - received 1ml of saline water orally. 
Group II - received 300mg/kg of squeezed leaf extract 
orally. 
Group III - received 300mg/kg of squeezed stem extract 
orally. 
Group IV - received 300mg/kg of squeezed root extract 
orally. 
Group V - received 300mg/kg of methanolic leaf extract 
orally.  
Group VI - received 300mg/kg of methanolic stem extract 
orally. 
Group VII - received 300mg/kg of methanolic root extract 
orally. 
Diabetic rats 
The animals were rested for 12 days and made diabetic by 
an inter-peritoneal administration of 150mg/kg alloxan 
monohydrate. After 5 days, the diabetic rats (glucose level 
˃350mg/dL or 5.0 Mmol/L) were regrouped into four groups 
of 5 rats each. 15 of the animals had died on the 1st and 2nd 
days after the alloxan injection administration. The four 
groups were subsequently treated as highlighted below: 
Group A (control) - received 1 ml of saline water orally. 
Group B - received 300 mg kg-1 of methanolic leaf extract 
orally. 
Group C - received 300 mg kg-1 of methanolic stem extract 
orally. 
Group D - received 300mg kg-1 of methanolic root extract 
orally.  
Estimation of blood glucose level  
Blood was collected from the tail vein of the rats and 
analysed for glucose using the One Touch Glucometer (Ames 
Gx Model, Germany). In both the normal and diabetic rats 
(i.e., a and b above), blood glucose was determined at  0, 1, 2 
and 4 hours.  
Statistical analysis 
The data were expressed as mean ± S.D. The significance 
of the data was determined using student’s t – test and were 
considered statistically significant when p ˂0.05.   
RESULTS AND DISCUSSION 
The percentage changes (%) in blood glucose level are as 
displayed in Tables 2, 4 and 6. These values were calculated 
as follows: 
%  Change = 100 GT /GO  
where   
GT =  Blood glucose level at time (t) = 1, 2 and 4 h;   
GO = Blood glucose level at time (t) = 0. 
Normoglycaemic rats 
The squeezed extracts of leaves, stem and roots of V. 
amygdalina were tested in normoglycaemic rats at 300mg/kg. 
The data obtained using the student’s t test showed no 
statistically significant difference in the normoglycaemic rats 
when compared to the control at t = 1, 2 and 4 h as can be 
seen in Table 2. This might be due to the preparation 
technique adopted which could have hindered the amount of 
plant materials filtered into these squeezed extract mixtures. 
However, the methanolic extracts of leaves and roots 
exhibited significantly (p˂0.05) and approximately similar 
hypoglycaemic activities in normoglycaemic rats especially 
at  t = 2 and 4 h which are remarkable.  These observations 
are as displayed in Table 4, 
Diabetic rats 
The methanolic extracts of leaves, stem and roots were 
equally tested in alloxan-induced rats at 300mg/kg.  It could 
be seen that the hypoglycaemic activities of the leaf and root 
extracts were highly pronounced (80% reduction in blood 
glucose level) but was evidently poor in the stem extract (20% 
reduction in blood glucose level). These observations are as 
presented in Table 6. The methanolic leaf and root extracts 
demonstrated significantly (p˂0.05) and approximately 
similar hypoglycaemic activities. These observations are not 
surprising because the extracts of V. amygdalina have been 
found to contain saponins, cardiac glycosides, tannins, 
flavonoids, terpenes, sugars, proteins, fats and vitamins C 
which have been implicated in previous studies to be 
hypoglycaemic.15,16  
It is very probable that any of these chemical constituents 
or a combination of them could be responsible for the 
hypoglycaemic activity demonstrated by the plant. Further 
studies might have to be done to isolate and identify these 
hypoglycaemic principles and mechanism of action 
investigated  
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Table 1. Blood glucose level (mmol L-1) in normoglycaemic rats using squeezed extracts. 
Group Extract Dose 0 h 1 h 2 h 4 h 
I Control 1 ml saline water 2.5 2.4 2.4 2.5 
II Leaf 300 mg kg-1 2.8 2.8 2.6 2.5 
III Stem 300 mg kg-1 3.1 3.1 2.9 2.8 
IV Root 300 mg kg-1 2.6 2.5 2.4 2.2 
Mean ± S. D.  n = 5 
 
Table 2. Percentage change in blood glucose level ((mmol L-1) in normoglycaemic rats using squeezed extracts. 
Group Extract Dose % 1 h 2 h 4 h 
I Control 1 ml saline water 100  96.3 98.2 99.3 
II Leaf 300 mg kg-1 100 100 92.9 89.3 
III Stem 300 mg kg-1 100  100 93.6 90.3 
IV Root 300 mg kg-1 100   96.1 92.3 84.6 
Mean ± S. D.  n = 5 
 
Table 3. Blood glucose level (mmol L-1) in normoglycaemic rats using methanolic extracts. 
Group Extract Dose 0 h 1 h 2 h 4 h 
I Control 1 ml saline water 2.5 2.4 2.4 2.5 
V Leaf 300mg/kg 2.8 2.7 2.5 2.1 
VI Stem 300mg/kg 2.8 2.7 2.6 2.7 
VII Root 300mg/kg 3.3 2.9 2.9 2.6 
Mean ± S. D.  n = 5 
 
Table 4. Percentage Change in Blood Glucose Level ((Mmol/L) in Normoglycaemic Rats using Methanolic Extracts. 
Group Extract Dose % 1 h 2 h 4 h 
I Control 1 ml saline water 100 96. 2 98.2 99.3 
V Leaf 300mg/kg 100 96.4 89.3 75.1 
VI Stem 300mg/kg 100 96.4       92.9 96.4 
VII Root 300mg/kg 100 87.9 87.9 78.8 
Mean ± S. D.  n = 5,  p˂0.05 
 
Table 5. Blood glucose level (mmol L-1) in alloxan-induced rats using methanolic extracts. 
Group Extract Dose 0 h 1 h 2 h 4 h 
A Control 1 ml saline water 11.6 10.5 10.8 10.5 
B Leaf 300mg/kg 11.6 8.8 7.4 3.5 
C Stem 300mg/kg       12.5 11.1 10.8 8.9 
D Root 300mg/kg 11.8 9.8 6.5 3.8 
Mean ± S. D.  n = 5 
 
Table 6. Percentage change in blood glucose level ((mmol L-1) in alloxan-induced rats using methanolic extracts. 
Group Extract Dose % 1 h 2 h 4 h 
A Control 1 ml saline water 100 90.8 93.1 90.3 
B Leaf 300mg/kg 100 76.3 63.7 30.1 
C Stem 300mg/kg 100 88.3 86.0 71.2 
D Root 300mg/kg 100 83.1 55.3 32.0 
Mean ± S. D.  n = 5, p˂0.05 
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Furthermore, the results from this study as displayed in 
Tables 4 and 6 have shown that only the leaf and root extracts 
have demonstrated remarkable hypoglycaemic activities. 
This observation clearly negates the claims in 10 that the stem 
in addition to the leaves and roots V. amygdalina are 
employed in the treatment and management of diabetes 
mellitus especially in South-Eastern parts of Nigeria. Alloxan 
destroys the beta cells of the pancreas leading to insulin 
defiency.4-5 Therefore, it is conceivable that the 
hypoglycaemic activities shown by the leaf and root extracts 
were not related to insulin secretion by the pancreatic cells 
but rather by other mechanisms of action. However, close 
monitoring of blood glucose concentration in humans is 
required in the use of the leaf and root extracts of V. 
amygdalina in the herbal therapy of diabetes mellitus to avoid 
hypoglycaemic shock.   
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Novel semiconductor-base nanotechnology is gradually moving into new applications in the world economy. Semiconductor application 
requires increasing of investigations in the direction of their properties. The primary criterion of semiconductor suitability for use in 
semiconductor devices is its electrical properties, particularly current carriers mobility. Therefore, the problem connected with the 
explanation of the experimental results of current carriers mobility on the base of theoretical formulas is very urgent. In the present paper 
current carriers mobility due to ionized impurity scattering is discussed and calculated using numerical methods. Calculations have been 
done for different temperatures and different range of current carriers concentration in InAs. 
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Introduction 
An integral part of the new technologies, among them 
nanotechnology, are semiconductor devices. They have no 
alternative because of the economy in electric power 
consumption, compactness of the equipment on accounts of 
the extraordinary density of element packing in circuits, 
longevity, full automation, simplicity in operation, duration of 
activity without maintenance, high reliability, and so on. As 
dimensions of devices shrink to the nanometer range, the 
range of their applications broadens. Wherein the principle of 
functioning of all semiconductor devices is determined by the 
electrical properties of the active part of devices-
semiconductor material, in particular, by the charge carriers 
mobility. Mobility determines the process of directed motion 
of charged particles in a semiconductor under the action of an 
electric field and gives enormous information about 
investigated materials. Therefore, a great practical and 
theoretical interest is the study of those processes that occurs 
when an electric field is applied to charge carriers. In this case, 
the charge carriers are in nonequilibrium conditions and 
transport phenomena arise that are related to the directional 
displacement of the charge carriers. There are several 
theoretical approaches to the study of transport phenomena.1,2 
The most common among them is the method of the 
Boltzmann kinetic equation, by means of which it is possible 
to calculate the mobility of charge carriers. An essential 
feature of nonequilibrium processes is that they depend 
substantially on the mechanism of interaction of the current 
carriers in the solid-state system, namely, their scattering by 
lattices such as atomic vibrations, impurity ions, etc. 
The calculation of mobility components is needed not only 
in the study of the theory of semiconductors but at the 
explanation of the experimental results of investigated 
transport phenomena in semiconductors. However appropriate 
components of mobility are expressed by very complicated 
formulas and their treatment requires a lot of time. In the age 
of computer technology, it is reasonable and necessary to use 
modern software tools, a universal package for analyzing and 
managing databases, developing custom applications, 
containing a wide range of analysis procedures for use in 
scientific research in order to interpret the experimental 
results obtained with high accuracy. Therefore, the goal of 
our paper is to calculate impurity scattering mobility 
numerically.
 
Theoretical introduction to ionized impurity 
scattering 
Of all possible scattering mechanisms of current carriers in 
semiconductors, scattering on ions of impurities practically 
always takes place in all semiconductors. The only exception 
is the very low temperatures near the temperature of the liquid 
helium. The electrical properties of semiconductors are 
determined by the presence of donor or acceptor impurities 
introduced into it. The reason is that impurity conductivity, as 
a rule, far exceeds the own conductivity of the semiconductor. 
The intrinsic conductivity of semiconductors is usually small, 
since the number of free electrons, for example, at room 
temperature is of the order of 1013–1014 cm–3. At the same 
time, the number of atoms in 1cm3 is ~1023 atoms. 
Impurity centers can be atoms or ions of chemical elements 
embedded in the lattice of a semiconductor, excess atoms or 
ions implanted in the interstices of the lattice and various 
other defects and distortions in the crystal lattice (empty knots, 
cracks, shifts arising when deformations of crystals, etc.). The 
technique of semiconductor devices requires semiconductors 
both of maximum purity and doped. As the degree of doping 
increases, the density of the current carriers increases. At low 
impurity concentrations, due to the considerable distance 
between the impurity atoms, there is no interaction between 
them. Impurities form local states in the forbidden band. 
Because of the small number of charge carriers in the allowed 
band, they obey to the Boltzmann statistics. When the degree 
of doping is increased, the distance between impurity atoms is 
reduced, that leads to interaction between them, overlapping 
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of wave functions of charge carriers. The law of the charge 
carrier distribution with respect to energies in the impurity 
band and the allowed zones obey to the statistics somewhat 
between Boltzmann and Fermi–Dirac.1–3 A substantial 
increase in the concentration of impurities leads to the 
confluence of the impurity band with the allowed band, and 
an allowed zone is formed. 
In this case, a large concentration of charge carriers obeys 
to the Fermi-Dirac statistics and the gas of such particles is 
called degenerate. Thus, the properties of the electron gas 
significantly differ in undoped and doped semiconductors. 
The reduced Fermi level ξ defines the degeneracy criteξrion. 
A clear division into degenerate and non-degenerate charge 
carrier gases is conditional and depends on the temperature. 
As the temperature increases, when the intrinsic conductivity 
appears, the particles distribution in the electron gas will 
approach to Boltzmann statistics and, conversely, as the 
temperature decreases, the particles distribution will 
increasingly differ from Boltzmann's. It is interesting that in 
semiconductors the charge carriers gas becomes degenerate at 
low temperatures. It is accepted to assume with error 8 %, 
that ξ = –2 is the degeneracy boundary for charge carrier gas 
between degeneracy and no degeneracy state. At ξ < –2 the 
charge carrier gas is nondegenerate, at ξ < –2-degenerate. 
Different physical phenomena are differently sensitive to the 
form of the charge carrier distribution, and hence to the 
boundaries of degeneracy and will be ascribed differently by 
Fermi levels. 
There exist many essential classical research works of 
Conwel and Weisskopf, Brooks–Herring (taking into account 
a screening effect), which considered the process of electron 
scattering by impurity centers in semiconductors.4,5 However, 
these models are valid for charge carriers gas of 
noninteracting particles, which obey to the classical Maxwell-
Boltzmann statistics and the charge carriers gas is non-
degenerate. The impurity scattering in the case of non-
degenerate charge carriers gas has been discussed by Mott.6 
However, often, impurity scattering has to be considered 
when it is not known when charge carriers gas is either 
degenerate or non-degenerate. Fortunately, there exists a 
Mansfield model for charge carriers scattering by impurity 
centers in semiconductor, which is valid for any distribution 
either degenerate or non-degenerate gas of current carriers in 
energy.7 That is why in given work Mansfield model has been 
programmed. 
Methodology 
The expression of ionized impurity scattering mobility is:6  
,                                                      (1) 
where 
,                                                         (2) 
 
,            (3) 
 
.                                                      (4) 
In order to find the mobility values at different temperatures 
and for different concentrations of the current carriers, it is 
necessary first to calculate the reduced Fermi levels 
determined from the formula:
 
 
,                (5) 
 
where n is the charge carriers concentration, and -F1/2(ξ)  
integral Fermi.   
From (5) equitation we derive: 
 
.                 (6) 
 
When the current carriers concentration is known at a given 
temperature and given effective mass, for finding the 
parameter ξ, it is necessary to solve the equation (6). For this, 
we transform it into: 
 
          (7) 
 
or 
 
            (8) 
 
where 
 
 
A solution of equation (8) gives the value of ξ parameter. 
We used the bisectors numerical method for the solution of 
(8) equitation. All programs were written in Matlab.
 
To calculate mobility (1) it is necessary to calculate another 
unknown parameter η  which is in (3) equitation and it needs 
to solve transcendental equation (9) to find the value of η : 
 
( 3) ( 3)eη ξη η−− = + .         (9) 
 
After calculation of ξ parameter we can transform (9) 
equitation and define η  using ξ value:  
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The root of the equation ( ) 0f η = gives the value of η  
which can be solved using the bisectors method. 
The alternative way of solution of transcendental equation 
(9) is a graphical solution. But this method is not sufficiently 
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meaning of arbitrary temperature and current carriers 
concentration. When solving (12) equitation, it is necessary to 
take into account that the equation is not defined in the region 
(–3, +3). These points need to be eliminated at the calculation 
by this method. 
Results 
As an example, the electrons mobility of n-InAs has been 
considered using this software. InAs is one of the 
semiconductors currently widely used in modern electronics 
and nanotechnology in the form of high-speed transistors and 
integrated circuits, IR photodetectors, injection lasers, among 
them in nanostructure of nanowires, structures with quantum 
dots InAs, etc. The behavior of the mobility for n-InAs due to 
scattering processes on impurity ions and its relation to 
temperature and doping concentration has been revealed. For 
this reason, there has been calculated mobility for 
temperatures: 77, 150, and 300 K for different values of 
electrons concentration in the range of 1016–1019 cm–3. When 
the electrons concentration changes in this interval, current 
carriers distribution in energy changes from non-degenerate 
to degenerate gas state. Results of the calculation of variation 
of the current carrier mobility with the concentration of 
electrons at different temperatures for n-InAs are presented in 
Figures 1–3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Calculated mobility due to scattering of electrons on 
impurity ions for electron concentration in the range of 1016–1017 
cm–3 at temperatures: 1 – 300 K, 2 – 150 K and 3 – 77 K. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Calculated mobility due to scattering of electrons on 
impurity ions for electron concentration in the range of 1017–1018 
cm–3 at temperatures: 1 – 300 K, 2 – 150 K and 3 – 77 K. 
 
 
 
 
 
 
 
 
Figure 3. Calculated mobility due to scattering of electrons on 
impurity ions for electron concentration in the range of 1018–1019 
cm–3 at temperatures: 1 – 300 K, 2 – 150 K and 3 – 77 K. 
It is clear that with rising temperature, mobility rises and 
with increasing of electrons concentration it falls. The results 
show that in experimental samples of InAs the impurities are 
all ionized in temperature range considered.8 
The contribution of the scattering on the ionized impurity 
into the total scattering increases with increasing of impurity 
concentration. At n~1017cm–3 it is not still dominating. At the 
decrease of temperature below 300 K, the contribution of 
impurity ions in the scattering of carriers increases too. But 
with decreasing of T from 300 up to 77 K deionization of 
impurity levels takes place, 
Comparison of experimental data of mobility in the InAs, 
containing an impurity in the range of 1016–1019 cm–3 with the 
theoretical ones shows that, of all possible scattering 
mechanisms in InAs, the only combination of scattering on 
ionized impurities and optical phonons explains the 
experimental results in the temperature range.8–10 The share of 
contribution of these scattering mechanisms into the total 
scattering is different at various temperatures and electrons 
concentration. 
Conclusion 
For interpreting the experimental results of current carriers 
mobility in semiconductors with high accuracy, there has 
been using modern software tools for numerical calculation of 
mobility due to impurity scattering. In given work model for 
mobility due to impurity scattering for the general case of any 
degree of degeneracy of the charge carriers has been 
programmed. The calculation has been made for the electrons 
mobility of n-InAs.  
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The waste from coal-based thermal power plants in the form of pond ash is utilized in making of environment-friendly cement mortar with 
using sand and cement. The mechanical properties like compressive strength under uniaxial stress of brick masonry and cement mortars 
prepared with the incorporation of pond ash into the cement mortar at various mixing ratios have been determined. The mathematical 
relationship of compressive stress values and the composition of brick, mortar and masonry have been developed. The compressive stress, 
strain and Young’s modulus values and their relationships have been determined. Using pond ash lead to an increase in the strength of the 
mortar and brick masonry prism prepared.  
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Introduction 
The usefulness of ash in building materials and civil 
engineering application has been known for a long time.1,2 
There are attempts to utilize pond ash in cement mortar in the 
brick masonry with replacement of cement and sand with 
various ratios as per IS 1905,3 IS 2250,4 Eurocode EC 6 and 
EN 1996-1-1.5 Mathematical models were also developed to 
characterize the relationships between the compressive 
strength and modulus of elasticity of brick, mortar and 
masonry mortar contains alternative replacement materials.6-
14.  
The present work includes the results about compression 
tests for masonry prisms prepared using reference mortar and 
pond ash modified mortar and the evaluation of relationships 
between the values of Young's modulus of elasticity (E) and 
the compressive strength for mortars prepared with various 
curing methods.  
Experimentals 
The locally available burnt clay brick, cement mortar with 
1:4 proportion (contained one par cement and four parts sand) 
and brick masonry prism specimen were prepared. The 
samples of clay brick, mortar cubes and brick masonry prism 
were cured at 3, 7 and 28 days period. For the preparation of 
modified mortars, ordinary Portland cement (53 grade), river 
sand (locally available) and pond ash (sample collected from 
Thermal Power Plant, Bhusawal, Dist Jalgaon, Maharashtra) 
were used. Pond ash samples were dried after collection from 
disposal sites. The ratio between binder and filler used in the 
experiments was 1:4. The filler means river sand is first 
replaced with pond ash with a percentage level of 
replacement from no replacement to fifty percentage 
(abbreviation used as: SR0-50). Replacement of cement at the 
same level named as CR0-50. The mortar sample was prepared 
and cured at 7 and 28 d periods before testing. The 
compression test set up with a capacity of 400 kN was used 
to determine compressive strength and value of strain for 
burnt clay brick, cement mortar cube and brick masonry 
prism prepared using pond ash partially replaced with cement 
and sand. The samples were tested for their ultimate load 
carrying capacity. Stress and strain values were obtained and 
recorded. Test set up for brick masonry prism and cement 
mortar specimen can be seen in the Electronic Supplementary 
Information (ESI Fig.1.).  
Result and discussion 
Compressive strength values were measured and given in 
Table 1 and 2. The compressive strength values for pond ash 
modified products, the values decrease with increasing the 
replacement level for both CR5-40 and SR30-50 samples. The 
values of compressive strength for pond ash modified mortar 
exceeds the control in case of SR5-35  samples. These values 
can be used to determine the elasticity modulus (E). 
The K, α and β values as constants for model Eqn. 1 were 
determined with fitting the experimental values.  
   𝑓𝑓𝑘𝑘 = K 𝑓𝑓b𝐚𝐚 𝑓𝑓m𝐛𝐛   (1) 
where,  
 𝑓𝑓k = characteristic strength of masonry prism (N mm-2) 
 𝑓𝑓b = Compressive strength of brick (N mm-2) 
 𝑓𝑓𝑚𝑚= Compressive strength of mortar (N mm-2) 
K=0.365 
α=0.455 and  
β=0.4  
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Table 1. Compressive strength values of prism, brick and mortar, along with a comparison of Fk (experimental and values obtained from 
Eqn. 2) for CR0-50 
 
 
Table 2. Compressive strength values of prism, brick and mortar, along with a comparison of Fk (experimental and values obtained from 
Eqn. 2) for SR0-50 
 
 
Figure 3. The plot of the equation between E and fm for pond ash modified mortar for 7 and 28 days curing 
Pond ash 
replacement  
fk experimental 
N mm-2 
Constant 
K 
Fb   
N mm-2 
α Fm   
N mm-2 
β fk  from Eqn.2  
N mm-2 
% Error 
CR-0 2.61 0.365 4.19 0.455 24.53 0.4 2.52 3.36 
CR-5 2.72 0.365 4.19 0.455 22.16 0.4 2.42 11.08 
CR-10 2.28 0.365 4.19 0.455 19.81 0.4 2.31 -1.27 
CR-15 2.42 0.365 4.19 0.455 15.89 0.4 2.12 12.47 
CR-20 2.56 0.365 4.19 0.455 19.62 0.4 2.30 9.84 
CR-25 2.22 0.365 4.19 0.455 19.36 0.4 2.29 -3.45 
CR-30 1.88 0.365 4.19 0.455 19.11 0.4 2.28 -21.55 
CR-35 1.79 0.365 4.19 0.455 16.99 0.4 2.17 -21.63 
CR-40 1.70 0.365 4.19 0.455 14.87 0.4 2.06 -21.25 
CR-45 1.47 0.365 4.19 0.455 13.14 0.4 1.96 -33.19 
CR-50 1.42 0.365 4.19 0.455 10.56 0.4 1.80 -26.95 
 
Pond ash 
replacement  
fk experimental 
N mm-2 
Constant K Fb   
N mm-2 
α Fm   
N mm-2 
β fk  from Eqn.2  
N mm-2 
% Error 
SR-0 2.61 0.365 4.19 0.455 24.53 0.4 2.52 3.36 
SR-5 3.15 0.365 4.19 0.455 26.91 0.4 2.61 16.96 
SR-10 3.14 0.365 4.19 0.455 29.31 0.4 2.71 13.83 
SR-15 3.19 0.365 4.19 0.455 31.69 0.4 2.79 12.51 
SR-20 3.61 0.365 4.19 0.455 34.06 0.4 2.87 20.42 
SR-25 3.63 0.365 4.19 0.455 39.14 0.4 3.04 16.45 
SR-30 3.25 0.365 4.19 0.455 44.22 0.4 3.19 2.02 
SR-35 3.06 0.365 4.19 0.455 38.21 0.4 3.01 1.71 
SR-40 2.87 0.365 4.19 0.455 32.20 0.4 2.81 1.97 
SR-45 2.63 0.365 4.19 0.455 29.44 0.4 2.71 -3.12 
SR-50 2.41 0.365 4.19 0.455 25.70 0.4 2.57 -6.32 
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The strength of brick prism is associated with the strengths 
of mortar and brick  
The relations between elasticity modulus and strength for 
reference mortar/prism and pond ash modified mortar/prisms 
can be used for further analysis of masonry structures. The 
equations for 7 and 28 d curing period for reference and pond 
ash modified mortar/ prism samples are shown in Table 3-4.  
Table 3. The equation for the relation between elasticity modulus 
(E) and Compressive strength (𝑓𝑓𝑚𝑚) for cement mortar 
Mortar mix Reference 
mortar 
Pond ash 
modified mortar 
CR 7 Days E=35.70 𝑓𝑓𝑚𝑚 E=31.25 𝑓𝑓𝑚𝑚 
SR 7 Days E=35.70 𝑓𝑓𝑚𝑚 E=43.75 𝑓𝑓𝑚𝑚 
CR 28 Days E=66.67 𝑓𝑓𝑚𝑚 E=66.67 𝑓𝑓𝑚𝑚 
SR 28 Days E=66.67 𝑓𝑓𝑚𝑚 E=112.50 𝑓𝑓𝑚𝑚 
 
Table 4. The equation for the relation between elasticity modulus 
(E) and compressive strength (𝑓𝑓k) for brick masonry prisms 
Mortar mix Reference 
mortar 
Pond ash 
modified mortar 
CR 7 Days E=83𝑓𝑓k E=108 𝑓𝑓k 
SR 7 Days E=83 𝑓𝑓k E=160 𝑓𝑓k 
CR 28 Days E=264𝑓𝑓k E=266.67 𝑓𝑓k 
SR 28 Days E=264𝑓𝑓k E=320 𝑓𝑓k 
 
If the strength of mortar prism is known, the values for 
elasticity modulus can be calculated by using these equations 
available in Tables 3 and 4.  
The compressive strength for pond ash modified mortar is 
higher for SR5-40 than CR5-50. The relation between elasticity 
modulus and compressive strength is obtained for 7 and 28 
days are curing periods for brick masonry and mortar for 
reference and pond ash modified mortar. The new 
mathematical model obtained in accordance with Eurocode 
EC 6 and EN 1996-1-1 related to pond ash modified mortars 
for brick masonry prism.  
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phenoxynicotinaldehydes as α-amylase inhibitors. A new general method based on the aromatic nucleophilic substitution reactions of 2-
chloronicotinaldehyde with differently substituted phenols in the presence of K2CO3 in dry dioxane was developed to furnish the 
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Introduction 
Diabetes Mellitus (DM) is an extended metabolic disease 
of several etiologies characterized by chronic hyperglycemia 
with a disorder of carbohydrate, fat and also protein 
metabolism. It includes a group of metabolic diseases 
characterized by hyperglycemia, in which blood sugar levels 
are elevated either from defects in insulin secretion, insulin 
action or both of them.1 Therefore, it is necessary to 
decrease postprandial hyperglycemia to treat diabetes.2 This 
can be achieved by the inhibition of carbohydrate-
hydrolyzing enzymes like α-amylase and α-glucosidase.3  
α-Amylase is responsible for the breakdown of long chain 
carbohydrates and α-glucosidase breaks down starch and 
disaccharides to glucose. They serve as the primary 
digestive enzymes and support in intestinal absorption. Both 
these enzymes are the potential targets in the development 
of lead compounds for the treatment of diabetes.4  
Many natural products from plants have been used for the 
treatment of diabetes.5-8 Various drugs are available for the 
cure of Type 2 diabetes like acarbose, biguanides, 
sulphonylureas, thiozolidinediones, etc.9,10 But they have 
also exhibited many undesired side effects like 
gastrointestinal side effects and thus signifying other 
effective substitutes.11 
The pyridine substructure is one of the most predominant 
heterocycles found in natural products, pharmaceuticals, and 
functional materials.12 In the recent past, novel derivatives 
of pyridine have been developed and found to have a large 
number of biological activities.13-20 The pyridine structure is 
found in natural compounds like nicotinic acid (vitamin B3) 
and pyridoxine (vitamin B6). Over 100 medications on the 
market today include pyridine rings, such as Lunesta, 
commonly used to treat insomnia,  
Singulair, widely used to treat asthma, Nexium, widely 
used to treat acid reflux, and Actos, widely used to treat 
Type II diabetes (Figure 1).21 
 
 
 
 
 
 
 
 
Figure 1. Some representative pyridine containing drugs 
The pyridine moiety is also found in structurally simple 
drugs like isoniazid22 and ethionamide23 (both prodrugs for 
inhibitors of inter alia enoyl-acyl carrier protein reductase; 
tuberculosis), amrinone (phosphodiesterase 3 inhibitor; heart 
failure) and bupicomide (dopamine β-hydroxylase inhibitor; 
hypertension).  
The high reactivity of pyridine allows for many possible 
chemical reactions.24-25 In continuation with our efforts on 
the synthesis of bioactive heterocyclic compounds,26-32 the 
present study was carried out to investigate the inhibitory 
potentials of substituted 2-phenoxynicotinaldehydes. 
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Results and discussion 
We have synthesized a series of substituted 2-
phenoxynicotinaldehydes by developing new reaction 
conditions. In the literature, various methods are reported 
for the aromatic nucleophilic substitution of 2-
chloronicotinaldehydes by substituted phenols.33-39 All these 
reported methods have some limitations. It requires high 
temperature and longer reaction time. Hence, there was a 
need to develop better reaction conditions for the synthesis 
of substituted 2-phenoxynicotinaldehydes from 2-
chloronicotinaldehydes. In accordance with our aim, we 
performed the reaction of 2-chloronicotinaldehyde (1, 10 
mmol) with phenol (2l, 10 mmol) in the presence of 
anhydrous K2CO3 (15 mmol) in dry dioxane at room 
temperature and exclusively obtained the corresponding 2-
phenoxynicotinaldehyde (3l) with 75 % yield. In the same 
conversion, use of 10 mmol (1 equiv.) of K2CO3 also 
furnished the 2-phenoxynicotinaldehyde (3l) but less than 
60 % yield, revealing that 15 mmol (1.5 equiv.) of K2CO3 is 
necessary for quantitative conversion of 2-
chloronicotinaldehydes to corresponding substituted 2-
phenoxynicotinaldehydes.  
To establish the generality of this new set of reaction 
condition, we performed the aromatic nucleophilic 
substitution reactions of 2-chloro-nicotinaldehyde with 
differently substituted phenols in the presence of K2CO3 in 
dry dioxane to furnish the corresponding substituted 2-
phenoxynicontinaldehydes with 70-80% yields (Scheme 1). 
1H and 13C NMR spectral data confirmed the structures of 
all the synthesized substituted 2-phenoxynicontinaldehydes. 
 
 
 
 
 
Scheme 1. Synthesis of substituted 2-phenoxy 
nicotinaldehydes 
Biological activity 
The enzyme inhibition activity was studied by agar 
diffusion method with some modifications.40 For evaluating 
the enzyme inhibitory activity, commercially available α-
amylase sample (from Hi media laboratory) was used. The 
synthesized compounds were dissolved in DMSO at 25 mg 
per ml concentration. A paper disc of 6 mm diameter from 
Hi media was impregnated with 10 µL of 1 % α-amylase 
solution. Subsequently, 10 µL of test compound solution 
was also impregnated to the enzyme discs.  Control discs 
were prepared by adding 10 µL of DMSO only. Control and 
test discs were placed on 1 % starch containing Agar gel 
plates (pH 6.5). These plates were incubated at 37 0C for 24 
h. After 24 h the plates were developed by Gram's iodine 
solution to observe the zone of clearance. Each zone was 
measured in millimetre (Table 1). 
Table 1. Disc and medium preparation 
Parameter Magnitude 
Concentration of enzyme 10 mg in 1 mL  
Concentration of test compound 25 mg in 1 mL 
Concentration of starch (substrate) 10 mg in 1 mL  
Volume of the substrate in each plate 8 mL  
Amount of substrate in each plate 80 mg 
Diameter of zone (mm) for blank 
without enzyme with DMSO 
Nil 
The zone of control was used to calculate the amount of 
starch hydrolyzed. The amount of starch hydrolyzed was 
calculated as shown in Table 2. The zone of clearance 
indicated the amount of starch hydrolyzed in milligrams. 
The amount of starch hydrolyzed by control was considered 
as 100 % activity and accordingly, % change in activity was 
measured. 
From Table 3, it is observed that all the tested compounds 
showed anti-α-amylase activity in the range from 25 % to 
59 %. Among these compounds 2i showed the least 
inhibition at 25.33 %, while compounds 2a, 2e, and 2g 
showed higher inhibition of more than 59 %. 
Table 2. Calculation for substrate consumed by control 
Value of π 3.14 
Thickness of medium, mm 1.01 
Diameter of zone (mm) for control (with only 
amylase and DMSO) 
22 
Radius of zone (mm) 11 
Volume of the reaction zone, mm3, 
[πr2*h (thickness of medium)] 
383.7394 
Amount of substrate consumed in control 
mg 
383.7394/100 
Table 3. Calculation of percent reduction in α-amylase 
activity 
Entry Diameter of 
the zone, 
mm 
Consumed 
substrate, 
mg 
Acti-
vity, 
% 
Activity 
fall, 
 % 
Control 22 3.83 100 0.00 
2a 14 1.54 40.2 59.8 
2b 15.5 1.89 49.34 50.66 
2c 15.5 1.89 49.34 50.66 
2d 16 2.01 52.48 47.52 
2e 14 1.54 40.2 59.8 
2f 16.5 2.14 55.87 44.13 
2g 14 1.55 40.47 59.53 
2h 15.5 1.9 49.6 50.4 
2i 19 2.86 74.67 25.33 
2j 15.5 1.89 49.34 50.66 
2k 16.5 2.14 55.87 44.13 
2l 17 2.27 59.26 40.74 
2m 18.2 2.6 67.88 32.12 
2n 17.6 2.43 63.44 36.56 
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Experimental 
General procedure for the synthesis substituted 2-
phenoxy-nicotinaldehydes 
2-Chloronicotinaldehyde (10 mmol), substituted phenols 
(10 mmol) and potassium carbonate (15 mmol) in dry 
dioxane were stirred at room temperature. The progress of 
the reaction was monitored by TLC. After completion of the 
reaction, the solvent was evaporated on a rotary evaporator. 
The reaction mixture was extracted by ethyl acetate. The 
crude product obtained was purified by recrystallization in 
ethanol to furnish the corresponding substituted 2-
phenoxynicotinaldehydes with 70-80% yields.  
2-(4-Chlorophenoxy)nicotinaldehyde (3a). 
Yield: 74 %; M.p.: 80-82 oC; 1H NMR (CDCl3, 400 
MHz): δ ppm = 7.15-7.19 (m, 3H), 7.41-7.45 (m, 2H), 8.27 
(dd, J = 8 and 2 Hz, 1H), 8.36 (dd, J = 7 and 2 Hz, 1H), 
10.56 (s, 1H); 13C NMR (CDCl3, 100 MHz): δ ppm = 119.32, 
119.52, 123.12, 129.80, 130.83, 138.34, 151.46, 152.99, 
163.72, 188.52. 
2-(2,4-Dichlorophenoxy)nicotinaldehyde (3b) 
Yield: 70 %; M.P.: 122-124 oC; 1H NMR (CDCl3, 400 
MHz): δ ppm = 7.17-7.20 (m, 1H), 7.26-7.28 (m, 1H), 7.34-
7.37 (m, 1H), 7.51-7.52 (m, 1H), 8.28 (dd, J = 8 and 2 Hz, 
1H), 8.31 (dd, J = 7 and 2 Hz, 1H), 10.60 (s, 1H); 13C NMR 
(CDCl3, 100 MHz): δ ppm = 119.10, 119.58, 125.15, 128.18, 
128.32, 130.41, 131.65, 138.41, 147.71, 152.85, 163.05, 
188.33. 
2-(2,5-Dichlorophenoxy)nicotinaldehyde (3c) 
Yield: 70 %; M.P.: 88-90 oC; 1H NMR (DMSO-d6, 400 
MHz): δ ppm = 7.38 (dd, J = 8 and 5 Hz, 1H), 7.44 (dd, J = 
8 and 2 Hz, 1H), 7.66-7.68 (m, 2H), 8.30 (dd, J = 8 and 2 Hz, 
1H), 8.40 (dd, J = 5 and 2 Hz, 1H), 10.44 (s, 1H). 
2-(p-Tolyloxy)nicotinaldehyde (3d) 
Yield: 80 %; M.P.: 78-80 oC; 1H NMR (CDCl3, 400 MHz): 
δ ppm = 2.41 (s, 3H), 7.10-7.14 (m, 3H), 7.26-7.28 (m, 2H),  
8.26 (dd, J = 8 and 2 Hz, 1H), 8.37 (dd, J = 5 and 2 Hz, 1H), 
10.59 (s, 1H); 13C NMR (CDCl3, 100 MHz): δ ppm = 20.94, 
118.79, 119.45, 121.45, 130.31, 135.13, 138.04, 150.73, 
153.19, 164.36, 188.94. 
2-(2-Bromophenoxy)nicotinaldehyde (3e) 
Yield: 76 %; M.P.: 83-85 oC; 1H NMR (CDCl3, 400 MHz): 
δ ppm = 7.15-7.22 (m, 2H), 7.23-7.34 (m, 1H), 7.42-7.46 (m, 
1H), 7.68-7.70 (m, 1H), 8.28-8.34 (m, 2H), 10.65 (s, 1H); 
13C NMR (CDCl3, 100 MHz): δ ppm = 116.68, 119.23, 
119.29, 124.38, 127.14, 128.67, 133.72, 138.21, 150.18, 
152.95, 163.36, 188.68. 
 
2-(o-Tolyloxy)nicotinaldehyde (3f) 
Yield: 78 %; M.P.: Thick oil; 1H NMR (CDCl3, 400 MHz): 
δ ppm = 2.23 (s, 3H), 7.10-7.20 (m, 2H), 7.22-7.34 (m, 3H), 
8.27 (dd, J = 8 and 2 Hz, 1H), 8.34 (dd, J = 5 and 2 Hz, 1H), 
10.64 (s, 1H); 13C NMR (CDCl3, 100 MHz): δ ppm = 16.51, 
118.74, 119.13, 122.13, 125.86, 127.20, 130.75, 131.46, 
138.17, 151.44, 153.30, 163.98, 188.77. 
2-(3,4-Dichlorophenoxy)nicotinaldehyde (3g) 
Yield: 72 %; M.P.: 82-84 oC; 1H NMR (CDCl3, 400 MHz): 
δ ppm = 7.09-7.20 (m, 1H), 7.20-7.22 (m, 1H), 7.37 (d, J = 
2 Hz, 1H),7.52 (d, J = 8Hz, 1H), 8.28 (dd, J = 8 and 2 Hz, 
1H), 8.36 (dd, J = 5 & 2Hz, 1H), 10.53 (s, 1H); 13C NMR 
(CDCl3, 100 MHz): δ ppm = 119.51, 119.72, 121.45, 124.04, 
129.32, 130.97, 133.23, 138.52, 151.68, 152.92, 163.23, 
188.18. 
2-(m-Tolyloxy)nicotinaldehyde (3h). 
Yield: 75 %; M.P.: 54-56 oC; 1H NMR (CDCl3, 400 MHz): 
δ ppm =  2.42 (s, 3H), 7.01-7.10 (m, 2H), 7.12-7.16 (m, 2H), 
7.34-7.38 (m, 1H), 8.26 (dd, J = 8 and 2Hz, 1H), 8.37 (dd, J 
= 5 and 2 Hz, 1H), 10.58 (s, 1H); 13C NMR (CDCl3, 100 
MHz): δ ppm = 21.43, 118.59, 118.91, 119.57, 122.19, 
126.33, 129.46, 138.06, 140.00, 153.07, 153.23, 164.23, 
188.90. 
2-(3-(Trifluoromethyl)phenoxy)nicotinaldehyde (3i) 
Yield: 70 %; M.P.: 50-52 oC; 1H NMR (CDCl3, 400 MHz): 
δ ppm = 7.19-7.22 (m, 1H), 7.29-7.62 (m, 4H), 8.29 (dd, J = 
8 and 2Hz, 1H), 8.37 (dd, J = 5 and 2 Hz, 1H), 10.57 (s, 
1H); 13C NMR (CDCl3, 100 MHz): δ ppm = 118.92,  119.00, 
119.60, 119.63, 122.17, 122.24, 125.26, 130.24, 138.47, 
152.94, 153.13, 163.36, 188.31. 
2-(3,5-Dichlorophenoxy)nicotinaldehyde (3j) 
Yield: 70 %; M.P.: 110-112 oC; 1H NMR (CDCl3, 400 
MHz): δ ppm =  7.17-7.22 (m, 2H), 7.23-7.24 (m, 1H), 7.29-
7.30 (m, 1H), 8.28 (dd, J = 8 and 2 Hz, 1H), 8.39 (dd, J = 5 
and 2 Hz, 1H), 10.51 (s, 1H); 13C NMR (CDCl3, 100 MHz): 
δ ppm = 119.62, 119.95, 120.83, 125.84, 135.50, 138.57, 
152.96, 153.80, 162.98, 188.04. 
2-(2-(Trifluoromethyl)phenoxy)nicotinaldehyde (3k) 
Yield: 77 %; M.P.: 50-52 oC; 1H NMR (CDCl3, 400 MHz): 
δ ppm = 7.17-7.21 (m, 1H), 7.39-7.43 (m, 2H), 7.65-7.67 (m, 
1H), 7.69-7.78 (m, 1H), 8.29 (dd, J = 8 and 2 Hz, 1H), 8.34 
(dd, J = 5 and 2 Hz, 1H), 10.58 (s, 1H); 13C NMR (CDCl3, 
100 MHz): δ ppm = 119.57, 121.76, 124.47, 125.52, 127.18, 
127.23, 127.28, 133.03, 138.24, 150.32, 152.77, 163.43, 
188.47. 
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2-Phenoxynicotinaldehyde (3l) 
Yield: 75 %; M.P.: 58-60 oC; 1H NMR (CDCl3, 400 MHz): 
δ ppm = 7.11-7.14 (m, 1H), 7.18-7.19 (m, 1H), 7.20-7.21 (m, 
1H), 7.26-7.30 (m, 1H), 7.44-7.48 (m, 2H), 8.25 (dd, J = 8 
and 2 Hz, 1H), 8.35 (dd, J = 5 and 2 Hz, 1H), 10.57 (s, 1H). 
2-(2-Chlorophenoxy)nicotinaldehyde (3m) 
Yield: 70 %; M.P.: 63-65 oC; 1H NMR (CDCl3, 400 MHz): 
δ ppm = 7.13-7.16 (m, 1H), 7.23-7.27 (m, 1H), 7.27-7.32 (m, 
1H), 7.35-7.38 (m, 1H), 7.50-7.52 (m, 1H), 8.27 (dd, J = 8 
and 2 Hz, 1H), 8.31 (dd, J = 5 and 2 Hz, 1H), 10.62 (s, 1H). 
2-(3-Chlorophenoxy)nicotinaldehyde (3n) 
Yield: 70 %; M.P.: 56-58 oC; 1H NMR (CDCl3, 400 MHz): 
δ ppm = 7.01-7.13 (m, 1H), 7.15-7.19 (m, 1H), 7.23-7.25 
(m, 1H), 7.26-7.27 (m, 1H), 7.35-7.40 (m, 1H), 8.26 (dd, J = 
8 and 2 Hz, 1H), 8.36 (dd, J = 5 and 2 Hz, 1H), 10.53 (s, 
1H). 
Conclusions 
We have reported a new method for aromatic nucleophilic 
substitution of 2-chloronicotinaldehyde by substituted 
phenols to furnish the corresponding substituted 2-
phenoxynicotinaldehydes. All the synthesized compounds 
showed anti-α-amylase activity. Among these compounds 
2a, 2e and 2g showed very good inhibition of more than 
59%. These three compounds can be subjected to in-vivo 
studies. 
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Production of metakaolin to increase the properties of cement and mortar has been studied from ordinary multicomponent mineral clays and 
shales as cheap raw materials. Alluvium clay shales formed as a result of mudflows were used as starting material and the optimal mode of 
its heat treatment has been elaborated to obtain the maximal amount of metakaolin. The pozzolanic properties of the heat-treated clay shales 
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INTRODUCTION 
Portland cement concrete products and reinforced concrete 
structures are considered as the most widely used building 
materials of the modern construction industry. The main 
advantages of Portland cement based concrete the reliability 
and durability, the resistance towards aggressive 
environments, the high physical and mechanical properties 
and the possibility of regulating key characteristics. Despite 
many remarkable features and accessibility of raw material 
components, the global problem is that concrete belongs to 
energy- and material-consuming construction materials. 
Herewith, the most expensive and energy intensive 
component of the concrete is cement, more precisely, its basis 
- clinker. In order to improve the construction and technical 
characteristics of types of cement and give them specific 
properties such as sulfate resistance, water resistance, 
durability, etc., a variety of pozzolan admixtures have been 
added, which additives effectively reduce the consumption of 
the clinker part of the cement, reduce fuel consumption.1,2 
A variety of materials containing silicon dioxide like 
geopolymers can be used as pozzolanic admixtures in cement 
production3–6 and other processes in the production of 
fertilizers, detergents, special glasses, ion exchangers and 
catalysts.7–10 In recent years, metakaolin as an active 
pozzolanic admixture to Portland cement has become very 
popular worldwide.11,12  Metakaolin creates an opportunity to 
increase the density, water resistance and strength of cement 
(due to its high specific surface area – up to 13000 cm2/g), 
and using it decreases the consumption of clinker. Metakaolin 
is obtained by heat treatment of kaolin clays, but the kaolin 
clay deposits availability is highly limited.  
Therefore, studies have been carried out to obtain 
metakaolin from ordinary multicomponent mineral clays and 
shales.13,14  
EXPERIMENTAL PART 
The thermal studies have been performed on a MOM Q-
1500D derivatograph (Hungary), with 10 0C min heating rate, 
in the air atmosphere, and with alumina standard.  
The X-ray phase analyzes were carried out using a Dron 1.5 
diffractometer (“Burevestnik”, St. Petersburg, Russia), with a 
Cu-anode and a graphite monochromator, intensity - 500 
imp/sec, time constant - 5 s, U = 35 kV, I = 20 mA. λ = 
1,54778 Å. 
RESULTS AND DISCUSSIONS 
Clay shales formed as a result of the accumulation of rocks 
collapsed due to mudflow stream to obtain metakaolin were 
removed from the bed and banks of the river Duruji. The 
phase analysis (XRD showed that the shales were the 
mixtures of hydromica, muscovite, biotite, pyrite, limonite, 
quartz, augite, sericite, calcite, plagioclase, orthoclase, 
chlorite.  The chemical composition of shales is presented in 
Table 1. 
The differential thermal analysis shows an endothermic 
effect between 100 and 150 °C corresponds to the removal of 
the physically or crystallization water. It is 4 % weight loss in 
the temperature range of 440–680 °C due to loss of 
constitutional water, while at 560–650 °C temperature an 
exothermic effect shows the burning out of organic inclusions 
and oxidizing of iron(II) content. In the temperature range of 
680–730°C there is noted an endothermic effect, which is the 
result of the destruction of the crystalline lattice and 
proceeding of active amorphization.  
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Table 1. Chemical composition of shales, wt.%. 
L.O.I. SiO2 TiO2 Al2O3 Fe2O3 FeO P2O5 MnO CaO MgO SO3 Na2O K2O 
0.40 59.95 1.02 17.30 5.80 1.30 0.26 0.21 1.53 2.43 0.30 2.20 2.20 
 
Based on the abovementioned results, the temperature 
range for the treatment of raw materials was selected to be 
between 600 and 800 °C. According to this, the temperature 
treatment of shales was performed at 600, 700 and 800 °C for 
2 and 3 h. 
X-ray phase analysis showed phase transformations of clay 
shales due to decomposition of components during the heat 
treatment (Figure 1). The diffractogram of natural shale 
(No.1) shows the presence of quartz (d=4.250, 3.340, 2.454, 
2.285, 2.238, 2.128, 2.000, 1.985, and 1.817 Å), clay mineral 
chlorite (d=14.14, 7.08, 4.73, 3.54, 2.88, and 2.383 Å), mica 
(d=9.96, 4.96, 2.564, and 2.000 Å), and Ca–Na feldspar 
(d=4.03, 3.78, 3.67, 3.20, 2.954, 3.000, 2.930, and 2.395 Å). 
On diffractograms of samples heat-treated at 600 °C for 2 and 
3 h (No.2 and 3, respectively), the amount of chlorite and 
mica decreases and an amorphous X-ray phase appears – the 
X-ray curve acquires a convex shape. On the diffractograms 
of samples heat-treated at 700 °C (2 and 3 h, No.4 and 5, 
respectively) the clay minerals completely disappear, the 
amount of mica is further reduced, and the amount of the 
amorphous phase is growing. The diffractograms of products 
formed at 800 °in 2 or 3 h (No. 6. and 7, respectively) are 
identical to diffractograms No.4 and 5, respectively. The 
decomposition of clay into amorphous pozzolanic oxides 
contain SiO2, Al2O3, and Fe2O3, which are able to bind 
calcium hydroxide to form insoluble calcium hydrosilicates, 
starts at 600 °C and this process is completed by raising the 
temperature to 800 °C.  
The reactivity of heat-treated clay shales towards lime is 
primarily due to the fact that at 600–800°C the main 
component of clay – inert kaolinite Al2O3·2SiO2·2H2O – is 
dehydrated and turns into the active kaolinite anhydride – 
metakaolin (Al2O3·2SiO2), in its amorphized form as a result 
of the removal of water. Addition of metakaolin into cement 
compositions promotes the formation of new hydrated 
phases. The active silica reacts with lime to form calcium 
hydrosilicates, the active alumina forms a stable 
hydroaluminates and hydrogаrnеts. As a result of the reaction 
of Ca2+ and Al3+ ions with an amorphous silica content of 
metakaolin, new compounds are created, including the strong 
mineral stratlingite C2ASH8.15,16 
X-ray phase analysis cannot be used to determine the 
amount of metakaolin due to its amorphous nature, but it is 
possible to determine the amount of active SiO2 (Table 2) and 
the kinetics of its growth by the method of chemical 
analysis.17 
According to Table 2, the maximum amount of active SiO2 
is formed in the temperature range of 700–800 °C. In this 
case, the exposure time is also essential; 2 h can be considered 
as optimal because with 3 h exposure, the sintering of the 
formed metakaolin occurs and it becomes less reactive. Thus, 
the optimal temperature treatment of clay shales was found to 
be 700-800°C with an exposure time of 2 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Diffraction patterns of shales: No.1 – natural (untreated 
shale), No.2 – heat-treated at 600 °C, 2 h exposure, No.3 – heat-
treated at 600 °C, 3 h exposure, No.4 – heat-treated at 700 °C, 2 h 
exposure, No.5 – heat-treated at 700 °C, 3 h exposure, No.6 – heat-
treated at 800 °C, 2 h exposure, and No.7 – heat-treated at 800 °C, 3 
h exposure. 
Table 2. Kinetics of growth of active SiO2 with increasing 
temperature and exposure time. 
No. Treatment 
temperature, °C 
Exposure, 
h 
Amount of active 
SiO2, wt.% 
    
1 Untreated – 10.21 
2 600 2 16.88 
3 600 3 20.64 
4 700 2 26.77 
5 700 3 21.00 
6 800 2 26.93 
7 800 3 19.56 
To determine the pozzolanic properties of heat-treated clay 
shales, cement samples were made according to the ASTM C 
311–05 standard. The test results are shown in Table 3. 
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Table 3. Physical-mechanical properties of cement samples. 
* Shale was processed at 800 °C with an exposure time of 2 h. 
According to ASTM C 618–05 the value of the “strength 
activity index” must obtain at least 75 % of the control 
mixture after 7 or 28 days. 
CONCLUSION 
The optimal mode of heat treatment of clay shales is 
heating at 800°C with an exposure time of 2 h. Shales 
processed in this way contain a certain amount of metakaolin 
and can be used as an active pozzolanic admixture to Portland 
cement. 
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Cement 
composition
, wt. % 
Compression 
strength, MPa 
Strength activity 
index, % 
7th day 28th day 7th day 28th day 
Clinker – 95 
Gypsum – 5 28.5 35.6 – – 
 
Clinker – 85 
Shale* – 10 
Gypsum –5 
31.2 37.9 109.5 106.5 
 
Clinker – 75 
Shale* – 20 
Gypsum-–5 
24.1 31.5 84.6 88.5 
